<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01307267</url>
  </required_header>
  <id_info>
    <org_study_id>B1641001</org_study_id>
    <secondary_id>2011-002799-17</secondary_id>
    <nct_id>NCT01307267</nct_id>
  </id_info>
  <brief_title>A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab</brief_title>
  <official_title>A PHASE 1 STUDY OF PF-05082566 AS A SINGLE AGENT IN PATIENTS WITH ADVANCED CANCER, AND IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA (NHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in patients with solid
      tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive
      Non-Hodgkin's Lymphoma (NHL).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 21, 2011</start_date>
  <completion_date type="Actual">February 20, 2019</completion_date>
  <primary_completion_date type="Actual">February 20, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Dose-Limiting Toxicities (DLTs) in First 2 Cycles of Portion A</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 2 Day 29 in Portion A (up to 57 days, each cycle = 28 days)</time_frame>
    <description>DLT: Any of the following adverse events (AEs) occurred in the first 2 cycles of treatment (up to 28 days post second dose) which was attributed to PF-05082566 alone for Portion A and not related to progressive disease. Hematologic: Grade 4 neutropenia lasting more than (&gt;)7 days; febrile neutropenia; neutropenic infection; Grade ≥3 thrombocytopenia with bleeding; Grade 4 thrombocytopenia; Grade ≥3 hemolysis. Non-Hematologic: Grade ≥3 toxicities, except those Grade 3 events that responded to treatment (eg, Grade 3 nausea, vomiting, diarrhea responding to standard medical supportive care within 48 hours would not be considered a DLT). Severity of AEs were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE). Each cycle=28 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With DLTs in First 2 Cycles of Portion B</measure>
    <time_frame>Cycle 1 Day 1 to Cycle 2 Day 29 in Portion B (up to 57 days, each cycle = 28 days)</time_frame>
    <description>DLT: Any of the following AEs occurred in the first 2 cycles of treatment (up to 28 days post second dose) which was attributed to PF-05082566 in combination with rituximab for Portion B and not related to progressive disease. Hematologic: Grade 4 neutropenia lasting more than (&gt;)7 days; febrile neutropenia; neutropenic infection; Grade ≥3 thrombocytopenia with bleeding; Grade 4 thrombocytopenia; Grade ≥3 hemolysis. Non-Hematologic: Grade ≥3 toxicities, except those Grade 3 events that responded to treatment (eg, Grade 3 nausea, vomiting, diarrhea responding to standard medical supportive care within 48 hours would not be considered a DLT). Severity of AEs were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE). Each cycle=28 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) in Portion A</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of dying); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. AEs included both non-serious AEs and SAEs. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study treatment. Causality of AEs was determined by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent AEs by Maximum National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Grade in Portion A</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study treatment. Severity of AEs were graded according to NCI CTCAE version 4.03 (Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hematology Laboratory Abnormalities by Maximum NCI CTCAE Grade in Portion A</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Following hematology laboratory abnormalities were graded per NCI CTCAE version 4.03: anemia, hemoglobin increased, lymphocyte count increased, lymphopenia, neutrophils (absolute), platelets, white blood cells. The abnormalities with at least 1 participant are presented here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Chemistries Laboratory Abnormalities by Maximum NCI CTCAE Grade in Portion A</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Following chemistries laboratory abnormalities were graded per NCI CTCAE version 4.03: alanine aminotransferase (ALT), Alkaline phosphatase, Aspartate aminotransferase (AST), bilirubin (total), creatinine, gamma glutamyl transferase (GGT), hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia. The abnormalities with at least 1 participant are presented here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Vital Sign Abnormalities in Portion A</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>For vital signs in Portion A, blood pressure and pulse rate were measured. Clinical significance was determined by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-05082566 Maximum Observed Serum Concentration (Cmax) in Portion A</measure>
    <time_frame>Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose</time_frame>
    <description>Cmax of PF-05082566 was observed directly from data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-05082566 Pre-dose Trough Concentration During Multiple Dosing (Ctrough) in Portion A</measure>
    <time_frame>Day 1 pre-dose of Cycle 2</time_frame>
    <description>Ctrough of PF-05082566 was observed directly from data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-05082566 Time for Maximum Observed Serum Concentration (Tmax) in Portion A</measure>
    <time_frame>Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.</time_frame>
    <description>Tmax of PF-05082566 was observed directly from data as time of Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-05082566 Area Under the Serum Concentration-Time Profile (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUClast) in Portion A</measure>
    <time_frame>Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.</time_frame>
    <description>AUClast of PF-05082566 was determined by linear/log trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-05082566 AUC From Time 0 to Infinity (AUCinf) in Portion A</measure>
    <time_frame>Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.</time_frame>
    <description>AUCinf = AUClast + (Clast*/kel), where Clast* is the estimated concentration at the time of the last measurable concentration and kel is the terminal phase rate constant calculated as the absolute value of the slope of a linear regression during the terminal phase of the natural log-transformed concentration time profile.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-05082566 AUC From Time 0 to Time of Dosing Interval (AUCtau) in Portion A</measure>
    <time_frame>Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.</time_frame>
    <description>AUCtau of PF-05082566 was determined using linear/log trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-05082566 Clearance (CL) in Portion A</measure>
    <time_frame>Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.</time_frame>
    <description>CL = Dose/AUCinf for Cycle 1 and Dose/AUCtau for Cycle 2. It was reported in units of milliliter per hour per kilogram (mL/hr/kg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-05082566 Volume of Distribution at Steady State (Vss) in Portion A</measure>
    <time_frame>Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.</time_frame>
    <description>Vss = CL × MRT, where CL is clearance and MRT is the mean residence time after intravenous administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive Anti-Drug Antibody (ADA) for PF-05082566 in Portion A</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>ADA for PF-05082566 was detected using electrochemiluminescence assay. Positive ADA for PF-05082566: titer&gt;=6.23.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With QTc Interval Meeting Categorical Summarization Criteria in Portion A</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Categorical summarization criteria for QTc interval (time from ECG Q wave to the end of the T wave corresponding to electrical systole corrected for heart rate): 1) absolute value of &gt;450 to &lt;=480 milliseconds (msec), &gt;480 to &lt;=500 msec, &gt;500 msec; 2) a maximum change from baseline of &gt;30 to &lt;=60 msec or &gt;60 msec.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Objective Response Per Response Evaluation Criteria in Solid Tumor (RECIST) Version 1.1 in Portion A</measure>
    <time_frame>Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)</time_frame>
    <description>Objective response: confirmed best overall response (BOR) of complete response (CR) or partial response (PR) per RECIST version 1.1. BOR of CR: target lesions and non-target diseases achieved CR, without new lesions. BOR of PR: target lesions achieved CR or PR while non-target diseases were non-CR/non-progression of disease (non-PD), indeterminate or missing, and without new lesions. For target lesions, CR: complete disappearance of all target lesions except nodal disease (target nodes must decrease to normal size); PR: &gt;=30% decrease under baseline of the sum of diameters of all target measurable lesions. For non-target diseases, CR: disappearance of all non-target lesions and normalization of tumor marker levels; non-CR/non-PD: persistence of any non-target lesions and/or tumor marker level above the normal limits; Indeterminate: progression had not been determined and &gt;=1 non-target sites were not assessed or assessment methods were inconsistent with those used at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response in Portion A</measure>
    <time_frame>Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)</time_frame>
    <description>Duration of response: the time from first documentation of objective response (confirmed BOR of CR or PR per RECIST version 1.1) to the date of first documentation of objective progression of disease (PD) or death due to any cause. Objective PD per RECIST version 1.1: &gt;=20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 millimeters (mm); or unequivocal progression of pre-existing lesions for non-target disease; or appearance of new lesions. This outcome measure reports the individual values for evaluable participants (instead of medians etc) due to the limited number of events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response in Portion A</measure>
    <time_frame>Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)</time_frame>
    <description>Time to response: the time from Cycle 1 Day 1 to the first documentation of objective response (confirmed BOR of CR or PR per RECIST version 1.1). BOR of CR: target lesions and non-target diseases achieved CR, without new lesions. BOR of PR: target lesions achieved CR or PR while non-target diseases were non-CR/non-PD, indeterminate or missing, and without new lesions. For target lesions, CR: complete disappearance of all target lesions except nodal disease (target nodes decreased to normal size); PR: &gt;=30% decrease under baseline of the sum of diameters of all target measurable lesions. For non-target diseases, CR: disappearance of all non-target lesions and normalization of tumor marker levels; non-CR/non-PD: persistence of any non-target lesions and/or tumor marker level above the normal limits; Indeterminate: progression had not been determined and &gt;=1 non-target sites were not assessed or assessment methods were inconsistent with those used at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival in Portion A</measure>
    <time_frame>Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)</time_frame>
    <description>Progression-free survival: the time from Cycle 1 Day 1 to the date of the first documentation of objective PD or death due to any cause, whichever occurred first. Objective PD per RECIST version 1.1: &gt;=20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm; or unequivocal progression of pre-existing lesions for non-target disease; or appearance of new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival in Portion A</measure>
    <time_frame>Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)</time_frame>
    <description>Overall survival was defined as the time from Cycle 1 Day 1 to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent AEs and SAEs in Portion B</measure>
    <time_frame>Up to approximately 4 years</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of dying); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. AEs included both non-serious AEs and SAEs. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study treatment. Causality of AEs was determined by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent AEs by Maximum NCI CTCAE Grade in Portion B</measure>
    <time_frame>Up to approximately 4 years</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study treatment. Severity of AEs were graded according to NCI CTCAE version 4.03 (Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hematology Laboratory Abnormalities by Maximum NCI CTCAE Grade in Portion B</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Following hematology laboratory abnormalities were graded per NCI CTCAE version 4.03: anemia, hemoglobin increased, lymphocyte count increased, lymphopenia, neutrophils (absolute), platelets, white blood cells. The abnormalities with at least 1 participant are presented here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Chemistries Laboratory Abnormalities by Maximum NCI CTCAE Grade in Portion B</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Following chemistries laboratory abnormalities were graded per NCI CTCAE version 4.03: alanine aminotransferase (ALT), Alkaline phosphatase, Aspartate aminotransferase (AST), bilirubin (total), creatinine, gamma glutamyl transferase (GGT), hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia. The abnormalities with at least 1 participant are presented here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Vital Sign Abnormalities in Portion B</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>For vital signs in Portion B, blood pressure, pulse rate, and body temperature were measured. Clinical significance was determined by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-05082566 Cmax in Portion B</measure>
    <time_frame>Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.</time_frame>
    <description>Cmax of PF-05082566 was observed directly from data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-05082566 Ctrough in Portion B</measure>
    <time_frame>Day 1 pre-dose of Cycle 2</time_frame>
    <description>Ctrough of PF-05082566 was observed directly from data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-05082566 Tmax in Portion B</measure>
    <time_frame>Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.</time_frame>
    <description>Tmax of PF-05082566 was observed directly from data as time of Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-05082566 AUClast in Portion B</measure>
    <time_frame>Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.</time_frame>
    <description>AUClast of PF-05082566 was determined by linear/log trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-05082566 AUCinf in Portion B</measure>
    <time_frame>Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose.</time_frame>
    <description>AUCinf = AUClast + (Clast*/kel), where Clast* is the estimated concentration at the time of the last measurable concentration and kel is the terminal phase rate constant calculated as the absolute value of the slope of a linear regression during the terminal phase of the natural log-transformed concentration time profile.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-05082566 AUCtau in Portion B</measure>
    <time_frame>Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.</time_frame>
    <description>AUCtau of PF-05082566 was determined using linear/log trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-05082566 CL in Portion B</measure>
    <time_frame>Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.</time_frame>
    <description>CL = Dose/AUCinf for Cycle 1 and Dose/AUCtau for Cycle 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-05082566 Vss in Portion B</measure>
    <time_frame>Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.</time_frame>
    <description>Vss = CL × MRT, where CL is clearance and MRT is the mean residence time after intravenous administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rituximab Cmax and Ctrough in Portion B</measure>
    <time_frame>Day 1 pre-dose of Cycle 2</time_frame>
    <description>Cmax and Ctrough of rituximab were observed directly from data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive ADA for PF-05082566 and Rituximab in Portion B</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>ADA for PF-05082566 and rituximab was detected using electrochemiluminescence assay. Positive ADA for PF-05082566: titer&gt;=6.23. Positive ADA for rituximab: titer&gt;=1.88.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With QTc Interval Meeting Categorical Summarization Criteria in Portion B</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Categorical summarization criteria for QTc interval: 1) absolute value of &gt;450 to &lt;=480 milliseconds (msec), &gt;480 to &lt;=500 msec, &gt;500 msec; 2) a maximum change from baseline of &gt;30 to &lt;=60 msec or &gt;60 msec.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Objective Response Per Cheson 2007 Criteria in Portion B</measure>
    <time_frame>Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)</time_frame>
    <description>Objective Response in Portion B was defined as BOR of CR or PR according to Cheson 2007 criteria. BOR of CR or PR per Cheson 2007: CR or PR of index lesions (complete disappearance of all detectable clinical and radiographic evidence of disease, all lymph nodes returned to normal size, spleen and/or liver if enlarged prior to therapy became normal or no longer palpable; or &gt;=50% decrease in the sum of the product diameters [SPD] of up to 6 index lesions, no increase in size of other nodes, liver or spleen), without PD of non-index lesions (ie, without: new nonnodal lesion, new nodal lesion &gt;=15 mm in greatest transverse diameter [GTD], unequivocal progression of existing non index lesions, bone marrow that was negative and is now positive, new circulating lymphoma cells in blood cell count and/or pleural fluid, new circulating blasts in the blood cell count), and without any new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response in Portion B</measure>
    <time_frame>Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)</time_frame>
    <description>Duration of Response in Portion B was defined, for participants with an objective response (BOR of CR or PR per Cheson 2007 criteria), as the time from first documentation of objective response to the date of first documentation of objective PD or death due to any cause. Objective PD per Cheson 2007 was defined as: PD of index lesions (&gt;=50% increase in SPD of previously involved sites from nadir), or PD of non-index lesions (new nonnodal lesion, new nodal lesion &gt;=15 mm in GTD, unequivocal progression of existing non index lesions, bone marrow that was negative and is now positive, new circulating lymphoma cells in blood cell count and/or pleural fluid, new circulating blasts in the blood cell count), or appearance of new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response in Portion B</measure>
    <time_frame>Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)</time_frame>
    <description>Time to response in Portion B was defined, for participants with an objective response (BOR of CR or PR per Cheson 2007 criteria), as the time from Cycle 1 Day 1 to the first documentation of objective response. BOR of CR or PR per Cheson 2007: CR or PR of index lesions (complete disappearance of all detectable clinical and radiographic evidence of disease, all lymph nodes returned to normal size, spleen and/or liver if enlarged prior to therapy became normal or no longer palpable; or &gt;=50% decrease in the SPD of up to 6 index lesions, no increase in size of other nodes, liver or spleen), without PD of non-index lesions (ie, without: new nonnodal lesion, new nodal lesion &gt;=15 mm in GTD, unequivocal progression of existing non index lesions, bone marrow that was negative and is now positive, new circulating lymphoma cells in blood cell count and/or pleural fluid, new circulating blasts in the blood cell count), and without any new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival in Portion B</measure>
    <time_frame>Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)</time_frame>
    <description>Progression-free survival in Portion B was defined as the time from Cycle 1 Day 1 to the date of the first documentation of objective PD (per Cheson 2007) or death due to any cause, whichever occurred first. Objective PD per Cheson 2007 was defined as: PD of index lesions (&gt;=50% increase in SPD of previously involved sites from nadir), or PD of non-index lesions (new nonnodal lesion, new nodal lesion &gt;=15 mm in GTD, unequivocal progression of existing non index lesions, bone marrow that was negative and is now positive, new circulating lymphoma cells in blood cell count and/or pleural fluid, new circulating blasts in the blood cell count), or appearance of new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival in Portion B</measure>
    <time_frame>Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)</time_frame>
    <description>Overall survival was defined as the time from Cycle 1 Day 1 to the date of death due to any cause.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biomarkers Linked With Immunomodulation and Cytokine Release</measure>
    <time_frame>Days 1, 14, 29 and 57</time_frame>
    <description>This was an exploratory endpoint and no data were collected.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Pharmacodynamic Biomarkers</measure>
    <time_frame>Days 1 and 21</time_frame>
    <description>This was an exploratory endpoint and no data were collected.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient-Reported Outcomes of PF-05082566 and Rituximab When Given in Combination in Follicular Lymphoma Participants</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>This was an exploratory endpoint and was not evaluated. Patient-reported outcome questionnaires were not completed as a result of administrative processing error.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">190</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Lymphoma, Follicular</condition>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Carcinoma, Renal Cell</condition>
  <condition>Carcinoma, Squamous Cell of Head and Neck</condition>
  <condition>Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>Portion A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-05082566 single agent in patients with advanced cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Portion B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-05082566 in combination with rituximab in patients with Non-Hodgkin's Lymphoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05082566</intervention_name>
    <description>Intravenous, Dose escalation, once per month</description>
    <arm_group_label>Portion A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Intravenous, 375 mg/m2, once per week for 4 weeks</description>
    <arm_group_label>Portion B</arm_group_label>
    <other_name>Rituxan, MabThera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05082566</intervention_name>
    <description>IV, Dose escalation, once per month</description>
    <arm_group_label>Portion B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Portion A: Histological or cytological diagnosis of advanced/metastatic solid tumor
             malignancy or B cell lymphoma, for which no curative therapy is available. Portion A
             expansion includes patients who have documented disease progression on a checkpoint
             inhibitor (anti CTLA 4, anti PD1/PD L1 antibodies) per RECIST criteria. Tumor types
             include metastatic melanoma, renal cell carcinoma (RCC), non-small cell lung cancer
             (NCSLC) and squamous cell carcinoma of the head and neck (SCCHN). Patients in the dose
             expansion stage are required to provide archival or baseline (obtained during the
             screening period) tumor biopsies.

          -  Portion B: Histological confirmed relapsed or refractory CD20 positive NHL for which
             no curative therapy is available. Patients enrolled in the expansion cohort must have
             archival tissue available, sampled within 6 months of study entry. The Expansion
             cohort includes patients with FL or DLBCL with relapsed or refractory disease.

          -  Measurable disease with at least one extranodal tumor mass &gt;1.0 cm in the greatest
             transverse diameter (GTD) or in the case of malignant lymph nodes &gt;1.5 cm in the GTD.

          -  ECOG performance status of ≤ 1.

          -  Adequate bone marrow function, for Portion A: absolute neutrophil count (ANC) ≥ 1.5 x
             109/L, platelet count ≥100 x 109/L, hemoglobin &gt;9.0 g/dL. For Portion B: ANC ≥ 1.0 x
             109/L, platelet count ≥ 75 x 109/L, and hemoglobin ≥ 8.0 g/dL. In both cases, patients
             must be transfusion independent at least 14 days prior to screening.

          -  Serum creatinine ≤ 2 x ULN or estimated creatinine clearance ≥ 50 ml/min.

          -  Total serum bilirubin ≤ 1.5 x ULN unless the patient has documented Gilbert syndrome
             and AST and ALT ≤ 2.5 x ULN.

        Exclusion Criteria

          -  Patients with known symptomatic brain metastases requiring steroids.

          -  Prior allogeneic hematopoietic stem cell transplant.

          -  Immunosuppressive regimens involving systemic corticosteroids within 14 days before
             the first dose of study treatment.

          -  Therapeutic or experimental monoclonal antibodies within 28 day or prior radiation
             therapy within 14 days of the first dose of study drug.

          -  Autoimmune disorders and other diseases that compromise or impair the immune system.

          -  Unstable or serious concurrent medical conditions in the previous 6 months.

          -  Prior therapy with any anti CD137 monoclonal antibody.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center-Investigational Drug Services</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037-0845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Diego Medical Center-La Jolla (Jacobs Medical Center/Thornton Hospital)</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Administration Office: Clinical Research Unit</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center, Drug Information Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Bowyer Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology-Oncology Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Diego Medical Center - Hillcrest</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Monica UCLA Hematology &amp; Oncology Clinic</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center Department of Pharmacy, Research</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Emory Clinic, Building A</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Woman's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center-West County</name>
      <address>
        <city>Creve Coeur</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes-Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110-1094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes-Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Infusion Center Pharmacy</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center- South County</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center - St. Peters</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas - M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'investigation clinique</name>
      <address>
        <city>RENNES cedex 9</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Ospedaliera-Univer. di Bologna Policlinico S. Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele di Milano</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akita University Hospital</name>
      <address>
        <city>Akita</city>
        <zip>010-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital of Japanese Foundation for Cancer Research</name>
      <address>
        <city>Tokyo</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1641001&amp;StudyName=A%20Study%20Of%20PF-05082566%20As%20A%20Single%20Agent%20And%20In%20Combination%20With%20Rituximab</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 28, 2011</study_first_submitted>
  <study_first_submitted_qc>February 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2011</study_first_posted>
  <results_first_submitted>January 31, 2020</results_first_submitted>
  <results_first_submitted_qc>March 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 17, 2020</results_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Non-Hodgkin's Lymphoma</keyword>
  <keyword>Advanced malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 6, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT01307267/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 2, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT01307267/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>There was 1 participant who was enrolled but withdrew the consent before starting any of the treatment arms; therefore, this participant was not included in the participant flow table.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Portion A: PF-05082566 0.006mg/kg</title>
          <description>Participants received PF-05082566 0.006 milligrams per kilogram (mg/kg) intravenously once every 4 weeks (q4wks) as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="P2">
          <title>Portion A: PF-05082566 0.03mg/kg</title>
          <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="P3">
          <title>Portion A: PF-05082566 0.06mg/kg</title>
          <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="P4">
          <title>Portion A: PF-05082566 0.12mg/kg</title>
          <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="P5">
          <title>Portion A: PF-05082566 0.18mg/kg</title>
          <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="P6">
          <title>Portion A: PF-05082566 0.24mg/kg</title>
          <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="P7">
          <title>Portion A: PF-05082566 0.3mg/kg</title>
          <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="P8">
          <title>Portion A: PF-05082566 0.6mg/kg</title>
          <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="P9">
          <title>Portion A: PF-05082566 1.2mg/kg</title>
          <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="P10">
          <title>Portion A: PF-05082566 2.4mg/kg</title>
          <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="P11">
          <title>Portion A: PF-05082566 5mg/kg</title>
          <description>Participants received PF-05082566 5mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="P12">
          <title>Portion A: PF-05082566 10mg/kg</title>
          <description>Participants received PF-05082566 10mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="P13">
          <title>Portion B: PF-05082566 0.03mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks in combination with rituximab (375 milligrams per square meter [mg/m^2] intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="P14">
          <title>Portion B: PF-05082566 0.06mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="P15">
          <title>Portion B: PF-05082566 0.12mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="P16">
          <title>Portion B: PF-05082566 0.18mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="P17">
          <title>Portion B: PF-05082566 0.24mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="P18">
          <title>Portion B: PF-05082566 0.3mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="P19">
          <title>Portion B: PF-05082566 0.6mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="P20">
          <title>Portion B: PF-05082566 1.2mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="P21">
          <title>Portion B: PF-05082566 2.4mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="P22">
          <title>Portion B: PF-05082566 5mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 5mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="P23">
          <title>Portion B: PF-05082566 10mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 10mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="42"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="31"/>
                <participants group_id="P10" count="5"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="11"/>
                <participants group_id="P13" count="3"/>
                <participants group_id="P14" count="3"/>
                <participants group_id="P15" count="4"/>
                <participants group_id="P16" count="3"/>
                <participants group_id="P17" count="3"/>
                <participants group_id="P18" count="3"/>
                <participants group_id="P19" count="4"/>
                <participants group_id="P20" count="32"/>
                <participants group_id="P21" count="3"/>
                <participants group_id="P22" count="5"/>
                <participants group_id="P23" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="3"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="2"/>
                <participants group_id="P17" count="2"/>
                <participants group_id="P18" count="2"/>
                <participants group_id="P19" count="2"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="41"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="30"/>
                <participants group_id="P10" count="5"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="11"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="1"/>
                <participants group_id="P18" count="1"/>
                <participants group_id="P19" count="2"/>
                <participants group_id="P20" count="32"/>
                <participants group_id="P21" count="3"/>
                <participants group_id="P22" count="5"/>
                <participants group_id="P23" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="26"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="21"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="9"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="1"/>
                <participants group_id="P18" count="1"/>
                <participants group_id="P19" count="2"/>
                <participants group_id="P20" count="8"/>
                <participants group_id="P21" count="1"/>
                <participants group_id="P22" count="2"/>
                <participants group_id="P23" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="2"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="3"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
                <participants group_id="P23" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="19"/>
                <participants group_id="P21" count="2"/>
                <participants group_id="P22" count="3"/>
                <participants group_id="P23" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who received at least 1 dose of PF-05082566 or rituximab.</population>
      <group_list>
        <group group_id="B1">
          <title>Portion A: PF-05082566 0.006mg/kg</title>
          <description>Participants received PF-05082566 0.006 milligrams per kilogram (mg/kg) intravenously once every 4 weeks (q4wks) as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="B2">
          <title>Portion A: PF-05082566 0.03mg/kg</title>
          <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="B3">
          <title>Portion A: PF-05082566 0.06mg/kg</title>
          <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="B4">
          <title>Portion A: PF-05082566 0.12mg/kg</title>
          <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="B5">
          <title>Portion A: PF-05082566 0.18mg/kg</title>
          <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="B6">
          <title>Portion A: PF-05082566 0.24mg/kg</title>
          <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="B7">
          <title>Portion A: PF-05082566 0.3mg/kg</title>
          <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="B8">
          <title>Portion A: PF-05082566 0.6mg/kg</title>
          <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="B9">
          <title>Portion A: PF-05082566 1.2mg/kg</title>
          <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="B10">
          <title>Portion A: PF-05082566 2.4mg/kg</title>
          <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="B11">
          <title>Portion A: PF-05082566 5mg/kg</title>
          <description>Participants received PF-05082566 5mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="B12">
          <title>Portion A: PF-05082566 10mg/kg</title>
          <description>Participants received PF-05082566 10mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="B13">
          <title>Portion B: PF-05082566 0.03mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks in combination with rituximab (375 milligrams per square meter [mg/m^2] intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="B14">
          <title>Portion B: PF-05082566 0.06mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="B15">
          <title>Portion B: PF-05082566 0.12mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="B16">
          <title>Portion B: PF-05082566 0.18mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="B17">
          <title>Portion B: PF-05082566 0.24mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="B18">
          <title>Portion B: PF-05082566 0.3mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="B19">
          <title>Portion B: PF-05082566 0.6mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="B20">
          <title>Portion B: PF-05082566 1.2mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="B21">
          <title>Portion B: PF-05082566 2.4mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="B22">
          <title>Portion B: PF-05082566 5mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 5mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="B23">
          <title>Portion B: PF-05082566 10mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 10mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="B24">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="3"/>
            <count group_id="B6" value="42"/>
            <count group_id="B7" value="3"/>
            <count group_id="B8" value="4"/>
            <count group_id="B9" value="31"/>
            <count group_id="B10" value="5"/>
            <count group_id="B11" value="6"/>
            <count group_id="B12" value="11"/>
            <count group_id="B13" value="3"/>
            <count group_id="B14" value="3"/>
            <count group_id="B15" value="4"/>
            <count group_id="B16" value="3"/>
            <count group_id="B17" value="3"/>
            <count group_id="B18" value="3"/>
            <count group_id="B19" value="4"/>
            <count group_id="B20" value="32"/>
            <count group_id="B21" value="3"/>
            <count group_id="B22" value="5"/>
            <count group_id="B23" value="4"/>
            <count group_id="B24" value="189"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="0"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="0"/>
                    <measurement group_id="B24" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="19"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="4"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="2"/>
                    <measurement group_id="B18" value="3"/>
                    <measurement group_id="B19" value="2"/>
                    <measurement group_id="B20" value="14"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="3"/>
                    <measurement group_id="B23" value="3"/>
                    <measurement group_id="B24" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="25"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="12"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="3"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="2"/>
                    <measurement group_id="B20" value="18"/>
                    <measurement group_id="B21" value="3"/>
                    <measurement group_id="B22" value="2"/>
                    <measurement group_id="B23" value="1"/>
                    <measurement group_id="B24" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="13"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="2"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="2"/>
                    <measurement group_id="B18" value="1"/>
                    <measurement group_id="B19" value="1"/>
                    <measurement group_id="B20" value="15"/>
                    <measurement group_id="B21" value="1"/>
                    <measurement group_id="B22" value="2"/>
                    <measurement group_id="B23" value="1"/>
                    <measurement group_id="B24" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="27"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="18"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="8"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="2"/>
                    <measurement group_id="B16" value="2"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="2"/>
                    <measurement group_id="B19" value="3"/>
                    <measurement group_id="B20" value="17"/>
                    <measurement group_id="B21" value="2"/>
                    <measurement group_id="B22" value="3"/>
                    <measurement group_id="B23" value="3"/>
                    <measurement group_id="B24" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="36"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="24"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="3"/>
                    <measurement group_id="B15" value="3"/>
                    <measurement group_id="B16" value="2"/>
                    <measurement group_id="B17" value="2"/>
                    <measurement group_id="B18" value="2"/>
                    <measurement group_id="B19" value="4"/>
                    <measurement group_id="B20" value="22"/>
                    <measurement group_id="B21" value="2"/>
                    <measurement group_id="B22" value="5"/>
                    <measurement group_id="B23" value="4"/>
                    <measurement group_id="B24" value="141"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="1"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="0"/>
                    <measurement group_id="B21" value="1"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="0"/>
                    <measurement group_id="B24" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="7"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="6"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="0"/>
                    <measurement group_id="B24" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="4"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="0"/>
                    <measurement group_id="B24" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unspecified</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="0"/>
                    <measurement group_id="B21" value="0"/>
                    <measurement group_id="B22" value="0"/>
                    <measurement group_id="B23" value="0"/>
                    <measurement group_id="B24" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Dose-Limiting Toxicities (DLTs) in First 2 Cycles of Portion A</title>
        <description>DLT: Any of the following adverse events (AEs) occurred in the first 2 cycles of treatment (up to 28 days post second dose) which was attributed to PF-05082566 alone for Portion A and not related to progressive disease. Hematologic: Grade 4 neutropenia lasting more than (&gt;)7 days; febrile neutropenia; neutropenic infection; Grade ≥3 thrombocytopenia with bleeding; Grade 4 thrombocytopenia; Grade ≥3 hemolysis. Non-Hematologic: Grade ≥3 toxicities, except those Grade 3 events that responded to treatment (eg, Grade 3 nausea, vomiting, diarrhea responding to standard medical supportive care within 48 hours would not be considered a DLT). Severity of AEs were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE). Each cycle=28 days.</description>
        <time_frame>Cycle 1 Day 1 to Cycle 2 Day 29 in Portion A (up to 57 days, each cycle = 28 days)</time_frame>
        <population>All participants who received at least 1 dose of PF-05082566 in the first 2 cycles of Portion A.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion A: PF-05082566 0.006mg/kg</title>
            <description>Participants received PF-05082566 0.006 milligrams per kilogram (mg/kg) intravenously once every 4 weeks (q4wks) as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion A: PF-05082566 0.03mg/kg</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion A: PF-05082566 0.06mg/kg</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion A: PF-05082566 0.12mg/kg</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion A: PF-05082566 0.18mg/kg</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion A: PF-05082566 0.24mg/kg</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion A: PF-05082566 0.3mg/kg</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion A: PF-05082566 0.6mg/kg</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion A: PF-05082566 1.2mg/kg</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion A: PF-05082566 2.4mg/kg</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion A: PF-05082566 5mg/kg</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O12">
            <title>Portion A: PF-05082566 10mg/kg</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Dose-Limiting Toxicities (DLTs) in First 2 Cycles of Portion A</title>
          <description>DLT: Any of the following adverse events (AEs) occurred in the first 2 cycles of treatment (up to 28 days post second dose) which was attributed to PF-05082566 alone for Portion A and not related to progressive disease. Hematologic: Grade 4 neutropenia lasting more than (&gt;)7 days; febrile neutropenia; neutropenic infection; Grade ≥3 thrombocytopenia with bleeding; Grade 4 thrombocytopenia; Grade ≥3 hemolysis. Non-Hematologic: Grade ≥3 toxicities, except those Grade 3 events that responded to treatment (eg, Grade 3 nausea, vomiting, diarrhea responding to standard medical supportive care within 48 hours would not be considered a DLT). Severity of AEs were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE). Each cycle=28 days.</description>
          <population>All participants who received at least 1 dose of PF-05082566 in the first 2 cycles of Portion A.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="31"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With DLTs in First 2 Cycles of Portion B</title>
        <description>DLT: Any of the following AEs occurred in the first 2 cycles of treatment (up to 28 days post second dose) which was attributed to PF-05082566 in combination with rituximab for Portion B and not related to progressive disease. Hematologic: Grade 4 neutropenia lasting more than (&gt;)7 days; febrile neutropenia; neutropenic infection; Grade ≥3 thrombocytopenia with bleeding; Grade 4 thrombocytopenia; Grade ≥3 hemolysis. Non-Hematologic: Grade ≥3 toxicities, except those Grade 3 events that responded to treatment (eg, Grade 3 nausea, vomiting, diarrhea responding to standard medical supportive care within 48 hours would not be considered a DLT). Severity of AEs were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE). Each cycle=28 days.</description>
        <time_frame>Cycle 1 Day 1 to Cycle 2 Day 29 in Portion B (up to 57 days, each cycle = 28 days)</time_frame>
        <population>All participants who received at least 1 dose of PF-05082566 and 1 dose of rituximab in the first 2 cycles of Portion B.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion B: PF-05082566 0.03mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks in combination with rituximab (375 milligrams per square meter [mg/m^2] intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion B: PF-05082566 0.06mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion B: PF-05082566 0.12mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion B: PF-05082566 0.18mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion B: PF-05082566 0.24mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion B: PF-05082566 0.3mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion B: PF-05082566 0.6mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion B: PF-05082566 1.2mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion B: PF-05082566 2.4mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion B: PF-05082566 5mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion B: PF-05082566 10mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With DLTs in First 2 Cycles of Portion B</title>
          <description>DLT: Any of the following AEs occurred in the first 2 cycles of treatment (up to 28 days post second dose) which was attributed to PF-05082566 in combination with rituximab for Portion B and not related to progressive disease. Hematologic: Grade 4 neutropenia lasting more than (&gt;)7 days; febrile neutropenia; neutropenic infection; Grade ≥3 thrombocytopenia with bleeding; Grade 4 thrombocytopenia; Grade ≥3 hemolysis. Non-Hematologic: Grade ≥3 toxicities, except those Grade 3 events that responded to treatment (eg, Grade 3 nausea, vomiting, diarrhea responding to standard medical supportive care within 48 hours would not be considered a DLT). Severity of AEs were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE). Each cycle=28 days.</description>
          <population>All participants who received at least 1 dose of PF-05082566 and 1 dose of rituximab in the first 2 cycles of Portion B.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="31"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) in Portion A</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of dying); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. AEs included both non-serious AEs and SAEs. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study treatment. Causality of AEs was determined by the investigator.</description>
        <time_frame>Up to approximately 2 years</time_frame>
        <population>All participants who received at least 1 dose of PF-05082566 in Portion A.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion A: PF-05082566 0.006mg/kg</title>
            <description>Participants received PF-05082566 0.006 milligrams per kilogram (mg/kg) intravenously once every 4 weeks (q4wks) as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion A: PF-05082566 0.03mg/kg</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion A: PF-05082566 0.06mg/kg</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion A: PF-05082566 0.12mg/kg</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion A: PF-05082566 0.18mg/kg</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion A: PF-05082566 0.24mg/kg</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion A: PF-05082566 0.3mg/kg</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion A: PF-05082566 0.6mg/kg</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion A: PF-05082566 1.2mg/kg</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion A: PF-05082566 2.4mg/kg</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion A: PF-05082566 5mg/kg</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O12">
            <title>Portion A: PF-05082566 10mg/kg</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) in Portion A</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of dying); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. AEs included both non-serious AEs and SAEs. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study treatment. Causality of AEs was determined by the investigator.</description>
          <population>All participants who received at least 1 dose of PF-05082566 in Portion A.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="31"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="39"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="26"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="5"/>
                    <measurement group_id="O12" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="13"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="8"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs related to PF-05082566</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="25"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="10"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs related to PF-05082566</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent AEs by Maximum National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Grade in Portion A</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study treatment. Severity of AEs were graded according to NCI CTCAE version 4.03 (Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE).</description>
        <time_frame>Up to approximately 2 years</time_frame>
        <population>All participants who received at least 1 dose of PF-05082566 in Portion A.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion A: PF-05082566 0.006mg/kg</title>
            <description>Participants received PF-05082566 0.006 milligrams per kilogram (mg/kg) intravenously once every 4 weeks (q4wks) as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion A: PF-05082566 0.03mg/kg</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion A: PF-05082566 0.06mg/kg</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion A: PF-05082566 0.12mg/kg</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion A: PF-05082566 0.18mg/kg</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion A: PF-05082566 0.24mg/kg</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion A: PF-05082566 0.3mg/kg</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion A: PF-05082566 0.6mg/kg</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion A: PF-05082566 1.2mg/kg</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion A: PF-05082566 2.4mg/kg</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion A: PF-05082566 5mg/kg</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O12">
            <title>Portion A: PF-05082566 10mg/kg</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent AEs by Maximum National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Grade in Portion A</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study treatment. Severity of AEs were graded according to NCI CTCAE version 4.03 (Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE).</description>
          <population>All participants who received at least 1 dose of PF-05082566 in Portion A.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="31"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="14"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="8"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="9"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hematology Laboratory Abnormalities by Maximum NCI CTCAE Grade in Portion A</title>
        <description>Following hematology laboratory abnormalities were graded per NCI CTCAE version 4.03: anemia, hemoglobin increased, lymphocyte count increased, lymphopenia, neutrophils (absolute), platelets, white blood cells. The abnormalities with at least 1 participant are presented here.</description>
        <time_frame>Up to approximately 2 years</time_frame>
        <population>All participants who received at least 1 dose of PF-05082566 in Portion A and had hematology laboratory test data.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion A: PF-05082566 0.006mg/kg</title>
            <description>Participants received PF-05082566 0.006 milligrams per kilogram (mg/kg) intravenously once every 4 weeks (q4wks) as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion A: PF-05082566 0.03mg/kg</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion A: PF-05082566 0.06mg/kg</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion A: PF-05082566 0.12mg/kg</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion A: PF-05082566 0.18mg/kg</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion A: PF-05082566 0.24mg/kg</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion A: PF-05082566 0.3mg/kg</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion A: PF-05082566 0.6mg/kg</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion A: PF-05082566 1.2mg/kg</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion A: PF-05082566 2.4mg/kg</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion A: PF-05082566 5mg/kg</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O12">
            <title>Portion A: PF-05082566 10mg/kg</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hematology Laboratory Abnormalities by Maximum NCI CTCAE Grade in Portion A</title>
          <description>Following hematology laboratory abnormalities were graded per NCI CTCAE version 4.03: anemia, hemoglobin increased, lymphocyte count increased, lymphopenia, neutrophils (absolute), platelets, white blood cells. The abnormalities with at least 1 participant are presented here.</description>
          <population>All participants who received at least 1 dose of PF-05082566 in Portion A and had hematology laboratory test data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="28"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anemia, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="20"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="12"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anemia, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="8"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anemia, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocyte count increased, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphopenia, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphopenia, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphopenia, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphopenia, Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (absolute), Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (absolute), Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (absolute), Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cells, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cells, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cells, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Chemistries Laboratory Abnormalities by Maximum NCI CTCAE Grade in Portion A</title>
        <description>Following chemistries laboratory abnormalities were graded per NCI CTCAE version 4.03: alanine aminotransferase (ALT), Alkaline phosphatase, Aspartate aminotransferase (AST), bilirubin (total), creatinine, gamma glutamyl transferase (GGT), hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia. The abnormalities with at least 1 participant are presented here.</description>
        <time_frame>Up to approximately 2 years</time_frame>
        <population>&quot;Number of Participants Analyzed&quot; represents all participants who received at least 1 dose of PF-05082566 in Portion A and had chemistries laboratory test data. &quot;Number Analyzed&quot; represents all participants who received at least 1 dose of PF-05082566 in Portion A and had data for the specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion A: PF-05082566 0.006mg/kg</title>
            <description>Participants received PF-05082566 0.006 milligrams per kilogram (mg/kg) intravenously once every 4 weeks (q4wks) as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion A: PF-05082566 0.03mg/kg</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion A: PF-05082566 0.06mg/kg</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion A: PF-05082566 0.12mg/kg</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion A: PF-05082566 0.18mg/kg</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion A: PF-05082566 0.24mg/kg</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion A: PF-05082566 0.3mg/kg</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion A: PF-05082566 0.6mg/kg</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion A: PF-05082566 1.2mg/kg</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion A: PF-05082566 2.4mg/kg</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion A: PF-05082566 5mg/kg</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O12">
            <title>Portion A: PF-05082566 10mg/kg</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Chemistries Laboratory Abnormalities by Maximum NCI CTCAE Grade in Portion A</title>
          <description>Following chemistries laboratory abnormalities were graded per NCI CTCAE version 4.03: alanine aminotransferase (ALT), Alkaline phosphatase, Aspartate aminotransferase (AST), bilirubin (total), creatinine, gamma glutamyl transferase (GGT), hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia. The abnormalities with at least 1 participant are presented here.</description>
          <population>&quot;Number of Participants Analyzed&quot; represents all participants who received at least 1 dose of PF-05082566 in Portion A and had chemistries laboratory test data. &quot;Number Analyzed&quot; represents all participants who received at least 1 dose of PF-05082566 in Portion A and had data for the specified category.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="28"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT, Grade 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Grade 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase, Grade 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="13"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase, Grade 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase, Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Grade 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Grade 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin (total), Grade 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin (total), Grade 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, Grade 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="22"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="19"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="5"/>
                    <measurement group_id="O12" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, Grade 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, Grade 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypercalcemia, Grade 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperglycemia, Grade 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="20"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="13"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="4"/>
                    <measurement group_id="O12" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperglycemia, Grade 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperglycemia, Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperkalemia, Grade 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperkalemia, Grade 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypermagnesemia, Grade 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="27"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypermagnesemia, Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="27"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypernatremia, Grade 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoalbuminemia, Grade 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="18"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="9"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoalbuminemia, Grade 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoalbuminemia, Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypocalcemia, Grade 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypocalcemia, Grade 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypocalcemia, Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia, Grade 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia, Grade 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypokalemia, Grade 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypokalemia, Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypokalemia, Grade 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypomagnesemia, Grade 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="27"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyponatremia, Grade 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="17"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="8"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyponatremia, Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="28"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypophosphatemia, Grade 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="27"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypophosphatemia, Grade 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="27"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Vital Sign Abnormalities in Portion A</title>
        <description>For vital signs in Portion A, blood pressure and pulse rate were measured. Clinical significance was determined by the investigator.</description>
        <time_frame>Up to approximately 2 years</time_frame>
        <population>All participants who received at least 1 dose of PF-05082566 in Portion A.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion A: PF-05082566 0.006mg/kg</title>
            <description>Participants received PF-05082566 0.006 milligrams per kilogram (mg/kg) intravenously once every 4 weeks (q4wks) as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion A: PF-05082566 0.03mg/kg</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion A: PF-05082566 0.06mg/kg</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion A: PF-05082566 0.12mg/kg</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion A: PF-05082566 0.18mg/kg</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion A: PF-05082566 0.24mg/kg</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion A: PF-05082566 0.3mg/kg</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion A: PF-05082566 0.6mg/kg</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion A: PF-05082566 1.2mg/kg</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion A: PF-05082566 2.4mg/kg</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion A: PF-05082566 5mg/kg</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O12">
            <title>Portion A: PF-05082566 10mg/kg</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Vital Sign Abnormalities in Portion A</title>
          <description>For vital signs in Portion A, blood pressure and pulse rate were measured. Clinical significance was determined by the investigator.</description>
          <population>All participants who received at least 1 dose of PF-05082566 in Portion A.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="31"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PF-05082566 Maximum Observed Serum Concentration (Cmax) in Portion A</title>
        <description>Cmax of PF-05082566 was observed directly from data.</description>
        <time_frame>Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose</time_frame>
        <population>All participants who received at least 1 dose of PF-05082566 in Portion A and had at least 1 of the PK parameters of interest. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion A: PF-05082566 0.006mg/kg</title>
            <description>Participants received PF-05082566 0.006 milligrams per kilogram (mg/kg) intravenously once every 4 weeks (q4wks) as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion A: PF-05082566 0.03mg/kg</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion A: PF-05082566 0.06mg/kg</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion A: PF-05082566 0.12mg/kg</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion A: PF-05082566 0.18mg/kg</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion A: PF-05082566 0.24mg/kg</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion A: PF-05082566 0.3mg/kg</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion A: PF-05082566 0.6mg/kg</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion A: PF-05082566 1.2mg/kg</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion A: PF-05082566 2.4mg/kg</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion A: PF-05082566 5mg/kg</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O12">
            <title>Portion A: PF-05082566 10mg/kg</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>PF-05082566 Maximum Observed Serum Concentration (Cmax) in Portion A</title>
          <description>Cmax of PF-05082566 was observed directly from data.</description>
          <population>All participants who received at least 1 dose of PF-05082566 in Portion A and had at least 1 of the PK parameters of interest. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
          <units>micrograms per milliliter (μg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="29"/>
                    <count group_id="O10" value="5"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1515" spread="12"/>
                    <measurement group_id="O2" value="0.4952" spread="34"/>
                    <measurement group_id="O3" value="1.014" spread="24"/>
                    <measurement group_id="O4" value="2.614" spread="23"/>
                    <measurement group_id="O5" value="4.219" spread="16"/>
                    <measurement group_id="O6" value="3.246" spread="30"/>
                    <measurement group_id="O7" value="7.038" spread="23"/>
                    <measurement group_id="O8" value="11.72" spread="28"/>
                    <measurement group_id="O9" value="18.02" spread="24"/>
                    <measurement group_id="O10" value="49.63" spread="24"/>
                    <measurement group_id="O11" value="97.75" spread="13"/>
                    <measurement group_id="O12" value="150.3" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="37"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="24"/>
                    <count group_id="O10" value="3"/>
                    <count group_id="O11" value="5"/>
                    <count group_id="O12" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1250" spread="NA">Geometric coefficient of variation (CV) was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O2" value="0.5049" spread="7"/>
                    <measurement group_id="O3" value="1.093" spread="47"/>
                    <measurement group_id="O4" value="3.408" spread="25"/>
                    <measurement group_id="O5" value="4.013" spread="25"/>
                    <measurement group_id="O6" value="2.955" spread="46"/>
                    <measurement group_id="O7" value="8.349" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O8" value="14.80" spread="24"/>
                    <measurement group_id="O9" value="17.61" spread="36"/>
                    <measurement group_id="O10" value="58.38" spread="33"/>
                    <measurement group_id="O11" value="101.6" spread="17"/>
                    <measurement group_id="O12" value="167.0" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PF-05082566 Pre-dose Trough Concentration During Multiple Dosing (Ctrough) in Portion A</title>
        <description>Ctrough of PF-05082566 was observed directly from data.</description>
        <time_frame>Day 1 pre-dose of Cycle 2</time_frame>
        <population>All participants who received at least 1 dose of PF-05082566 in Portion A and had data for Ctrough.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion A: PF-05082566 0.006mg/kg</title>
            <description>Participants received PF-05082566 0.006 milligrams per kilogram (mg/kg) intravenously once every 4 weeks (q4wks) as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion A: PF-05082566 0.03mg/kg</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion A: PF-05082566 0.06mg/kg</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion A: PF-05082566 0.12mg/kg</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion A: PF-05082566 0.18mg/kg</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion A: PF-05082566 0.24mg/kg</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion A: PF-05082566 0.3mg/kg</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion A: PF-05082566 0.6mg/kg</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion A: PF-05082566 1.2mg/kg</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion A: PF-05082566 2.4mg/kg</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion A: PF-05082566 5mg/kg</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O12">
            <title>Portion A: PF-05082566 10mg/kg</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>PF-05082566 Pre-dose Trough Concentration During Multiple Dosing (Ctrough) in Portion A</title>
          <description>Ctrough of PF-05082566 was observed directly from data.</description>
          <population>All participants who received at least 1 dose of PF-05082566 in Portion A and had data for Ctrough.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="37"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="24"/>
                <count group_id="O10" value="3"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Geometric mean cannot be calculated when there were participants with a zero value (ie, Ctrough below the limit of quantification). Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O2" value="0.1063" spread="24"/>
                    <measurement group_id="O3" value="0.1092" spread="24"/>
                    <measurement group_id="O4" value="0.3268" spread="12"/>
                    <measurement group_id="O5" value="0.4285" spread="49"/>
                    <measurement group_id="O6" value="0.3868" spread="46"/>
                    <measurement group_id="O7" value="0.8597" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O8" value="1.520" spread="22"/>
                    <measurement group_id="O9" value="1.313" spread="61"/>
                    <measurement group_id="O10" value="7.054" spread="52"/>
                    <measurement group_id="O11" value="9.934" spread="35"/>
                    <measurement group_id="O12" value="9.963" spread="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PF-05082566 Time for Maximum Observed Serum Concentration (Tmax) in Portion A</title>
        <description>Tmax of PF-05082566 was observed directly from data as time of Cmax.</description>
        <time_frame>Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.</time_frame>
        <population>All participants who received at least 1 dose of PF-05082566 in Portion A and had at least 1 of the PK parameters of interest. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion A: PF-05082566 0.006mg/kg</title>
            <description>Participants received PF-05082566 0.006 milligrams per kilogram (mg/kg) intravenously once every 4 weeks (q4wks) as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion A: PF-05082566 0.03mg/kg</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion A: PF-05082566 0.06mg/kg</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion A: PF-05082566 0.12mg/kg</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion A: PF-05082566 0.18mg/kg</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion A: PF-05082566 0.24mg/kg</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion A: PF-05082566 0.3mg/kg</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion A: PF-05082566 0.6mg/kg</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion A: PF-05082566 1.2mg/kg</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion A: PF-05082566 2.4mg/kg</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion A: PF-05082566 5mg/kg</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O12">
            <title>Portion A: PF-05082566 10mg/kg</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>PF-05082566 Time for Maximum Observed Serum Concentration (Tmax) in Portion A</title>
          <description>Tmax of PF-05082566 was observed directly from data as time of Cmax.</description>
          <population>All participants who received at least 1 dose of PF-05082566 in Portion A and had at least 1 of the PK parameters of interest. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
          <units>hours (hr)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="29"/>
                    <count group_id="O10" value="5"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" lower_limit="1.50" upper_limit="2.00"/>
                    <measurement group_id="O2" value="1.63" lower_limit="1.50" upper_limit="1.67"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.00" upper_limit="5.42"/>
                    <measurement group_id="O4" value="1.26" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O5" value="1.25" lower_limit="0.967" upper_limit="6.00"/>
                    <measurement group_id="O6" value="1.03" lower_limit="0.833" upper_limit="24.2"/>
                    <measurement group_id="O7" value="1.00" lower_limit="1.00" upper_limit="1.50"/>
                    <measurement group_id="O8" value="1.80" lower_limit="1.62" upper_limit="2.00"/>
                    <measurement group_id="O9" value="1.17" lower_limit="1.00" upper_limit="5.53"/>
                    <measurement group_id="O10" value="1.50" lower_limit="1.00" upper_limit="1.58"/>
                    <measurement group_id="O11" value="1.06" lower_limit="1.00" upper_limit="1.48"/>
                    <measurement group_id="O12" value="1.50" lower_limit="1.07" upper_limit="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="37"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="24"/>
                    <count group_id="O10" value="3"/>
                    <count group_id="O11" value="5"/>
                    <count group_id="O12" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" lower_limit="2.00" upper_limit="24.0"/>
                    <measurement group_id="O2" value="1.50" lower_limit="1.50" upper_limit="2.00"/>
                    <measurement group_id="O3" value="1.54" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O4" value="1.00" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O5" value="2.00" lower_limit="1.50" upper_limit="2.00"/>
                    <measurement group_id="O6" value="1.03" lower_limit="0.833" upper_limit="2.00"/>
                    <measurement group_id="O7" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O8" value="1.46" lower_limit="1.00" upper_limit="1.70"/>
                    <measurement group_id="O9" value="1.02" lower_limit="0.883" upper_limit="1.22"/>
                    <measurement group_id="O10" value="1.08" lower_limit="1.00" upper_limit="1.08"/>
                    <measurement group_id="O11" value="1.92" lower_limit="1.08" upper_limit="2.00"/>
                    <measurement group_id="O12" value="1.31" lower_limit="1.03" upper_limit="5.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PF-05082566 Area Under the Serum Concentration-Time Profile (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUClast) in Portion A</title>
        <description>AUClast of PF-05082566 was determined by linear/log trapezoidal method.</description>
        <time_frame>Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.</time_frame>
        <population>All participants who received at least 1 dose of PF-05082566 in Portion A and had at least 1 of the PK parameters of interest. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion A: PF-05082566 0.006mg/kg</title>
            <description>Participants received PF-05082566 0.006 milligrams per kilogram (mg/kg) intravenously once every 4 weeks (q4wks) as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion A: PF-05082566 0.03mg/kg</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion A: PF-05082566 0.06mg/kg</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion A: PF-05082566 0.12mg/kg</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion A: PF-05082566 0.18mg/kg</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion A: PF-05082566 0.24mg/kg</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion A: PF-05082566 0.3mg/kg</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion A: PF-05082566 0.6mg/kg</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion A: PF-05082566 1.2mg/kg</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion A: PF-05082566 2.4mg/kg</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion A: PF-05082566 5mg/kg</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O12">
            <title>Portion A: PF-05082566 10mg/kg</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>PF-05082566 Area Under the Serum Concentration-Time Profile (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUClast) in Portion A</title>
          <description>AUClast of PF-05082566 was determined by linear/log trapezoidal method.</description>
          <population>All participants who received at least 1 dose of PF-05082566 in Portion A and had at least 1 of the PK parameters of interest. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
          <units>microgram*hour per milliliter (μg*hr/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="34"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="27"/>
                    <count group_id="O10" value="5"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.212" spread="251"/>
                    <measurement group_id="O2" value="101.0" spread="9"/>
                    <measurement group_id="O3" value="148.1" spread="33"/>
                    <measurement group_id="O4" value="389.4" spread="58"/>
                    <measurement group_id="O5" value="703.3" spread="32"/>
                    <measurement group_id="O6" value="481.1" spread="48"/>
                    <measurement group_id="O7" value="996.1" spread="29"/>
                    <measurement group_id="O8" value="2165" spread="21"/>
                    <measurement group_id="O9" value="2383" spread="61"/>
                    <measurement group_id="O10" value="5731" spread="101"/>
                    <measurement group_id="O11" value="15540" spread="22"/>
                    <measurement group_id="O12" value="25520" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="3"/>
                    <count group_id="O11" value="5"/>
                    <count group_id="O12" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.21" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O2" value="105.2" spread="49"/>
                    <measurement group_id="O3" value="93.59" spread="152"/>
                    <measurement group_id="O4" value="614.9" spread="7"/>
                    <measurement group_id="O5" value="808.0" spread="53"/>
                    <measurement group_id="O6" value="818.7" spread="38"/>
                    <measurement group_id="O7" value="1662" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O8" value="1918" spread="40"/>
                    <measurement group_id="O9" value="4035" spread="25"/>
                    <measurement group_id="O10" value="6741" spread="6"/>
                    <measurement group_id="O11" value="18140" spread="24"/>
                    <measurement group_id="O12" value="19900" spread="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PF-05082566 AUC From Time 0 to Infinity (AUCinf) in Portion A</title>
        <description>AUCinf = AUClast + (Clast*/kel), where Clast* is the estimated concentration at the time of the last measurable concentration and kel is the terminal phase rate constant calculated as the absolute value of the slope of a linear regression during the terminal phase of the natural log-transformed concentration time profile.</description>
        <time_frame>Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.</time_frame>
        <population>All participants who received at least 1 dose of PF-05082566 in Portion A and had at least 1 of the PK parameters of interest. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion A: PF-05082566 0.006mg/kg</title>
            <description>Participants received PF-05082566 0.006 milligrams per kilogram (mg/kg) intravenously once every 4 weeks (q4wks) as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion A: PF-05082566 0.03mg/kg</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion A: PF-05082566 0.06mg/kg</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion A: PF-05082566 0.12mg/kg</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion A: PF-05082566 0.18mg/kg</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion A: PF-05082566 0.24mg/kg</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion A: PF-05082566 0.3mg/kg</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion A: PF-05082566 0.6mg/kg</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion A: PF-05082566 1.2mg/kg</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion A: PF-05082566 2.4mg/kg</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion A: PF-05082566 5mg/kg</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O12">
            <title>Portion A: PF-05082566 10mg/kg</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>PF-05082566 AUC From Time 0 to Infinity (AUCinf) in Portion A</title>
          <description>AUCinf = AUClast + (Clast*/kel), where Clast* is the estimated concentration at the time of the last measurable concentration and kel is the terminal phase rate constant calculated as the absolute value of the slope of a linear regression during the terminal phase of the natural log-transformed concentration time profile.</description>
          <population>All participants who received at least 1 dose of PF-05082566 in Portion A and had at least 1 of the PK parameters of interest. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
          <units>μg*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="21"/>
                    <count group_id="O10" value="2"/>
                    <count group_id="O11" value="4"/>
                    <count group_id="O12" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="120" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O3" value="187.5" spread="31"/>
                    <measurement group_id="O4" value="667.0" spread="13"/>
                    <measurement group_id="O5" value="989.5" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O6" value="687.9" spread="43"/>
                    <measurement group_id="O7" value="770.0" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O8" value="2916" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O9" value="3111" spread="36"/>
                    <measurement group_id="O10" value="7628" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O11" value="18430" spread="24"/>
                    <measurement group_id="O12" value="28280" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="1"/>
                    <count group_id="O11" value="3"/>
                    <count group_id="O12" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="169.8" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O3" value="251.4" spread="17"/>
                    <measurement group_id="O4" value="931.0" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O5" value="1072" spread="57"/>
                    <measurement group_id="O6" value="960.8" spread="47"/>
                    <measurement group_id="O7" value="2000" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O8" value="1782" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O9" value="4649" spread="25"/>
                    <measurement group_id="O10" value="8480" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O11" value="20950" spread="23"/>
                    <measurement group_id="O12" value="22400" spread="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PF-05082566 AUC From Time 0 to Time of Dosing Interval (AUCtau) in Portion A</title>
        <description>AUCtau of PF-05082566 was determined using linear/log trapezoidal method.</description>
        <time_frame>Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.</time_frame>
        <population>All participants who received at least 1 dose of PF-05082566 in Portion A and had at least 1 of the PK parameters of interest. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion A: PF-05082566 0.006mg/kg</title>
            <description>Participants received PF-05082566 0.006 milligrams per kilogram (mg/kg) intravenously once every 4 weeks (q4wks) as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion A: PF-05082566 0.03mg/kg</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion A: PF-05082566 0.06mg/kg</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion A: PF-05082566 0.12mg/kg</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion A: PF-05082566 0.18mg/kg</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion A: PF-05082566 0.24mg/kg</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion A: PF-05082566 0.3mg/kg</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion A: PF-05082566 0.6mg/kg</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion A: PF-05082566 1.2mg/kg</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion A: PF-05082566 2.4mg/kg</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion A: PF-05082566 5mg/kg</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O12">
            <title>Portion A: PF-05082566 10mg/kg</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>PF-05082566 AUC From Time 0 to Time of Dosing Interval (AUCtau) in Portion A</title>
          <description>AUCtau of PF-05082566 was determined using linear/log trapezoidal method.</description>
          <population>All participants who received at least 1 dose of PF-05082566 in Portion A and had at least 1 of the PK parameters of interest. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
          <units>μg*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="32"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="25"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.70" spread="181"/>
                    <measurement group_id="O2" value="104.8" spread="9"/>
                    <measurement group_id="O3" value="154.2" spread="27"/>
                    <measurement group_id="O4" value="503.9" spread="14"/>
                    <measurement group_id="O5" value="690.9" spread="33"/>
                    <measurement group_id="O6" value="538.6" spread="33"/>
                    <measurement group_id="O7" value="1012" spread="27"/>
                    <measurement group_id="O8" value="2195" spread="21"/>
                    <measurement group_id="O9" value="2761" spread="34"/>
                    <measurement group_id="O10" value="8204" spread="36"/>
                    <measurement group_id="O11" value="15760" spread="20"/>
                    <measurement group_id="O12" value="25250" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="1"/>
                    <count group_id="O11" value="5"/>
                    <count group_id="O12" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="130.8" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O3" value="224.4" spread="19"/>
                    <measurement group_id="O4" value="618.6" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O5" value="864.1" spread="47"/>
                    <measurement group_id="O6" value="824.3" spread="37"/>
                    <measurement group_id="O7" value="1681" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O8" value="2107" spread="43"/>
                    <measurement group_id="O9" value="4068" spread="27"/>
                    <measurement group_id="O10" value="7460" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O11" value="19040" spread="18"/>
                    <measurement group_id="O12" value="20490" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PF-05082566 Clearance (CL) in Portion A</title>
        <description>CL = Dose/AUCinf for Cycle 1 and Dose/AUCtau for Cycle 2. It was reported in units of milliliter per hour per kilogram (mL/hr/kg).</description>
        <time_frame>Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.</time_frame>
        <population>All participants who received at least 1 dose of PF-05082566 in Portion A and had at least 1 of the PK parameters of interest. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion A: PF-05082566 0.006mg/kg</title>
            <description>Participants received PF-05082566 0.006 milligrams per kilogram (mg/kg) intravenously once every 4 weeks (q4wks) as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion A: PF-05082566 0.03mg/kg</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion A: PF-05082566 0.06mg/kg</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion A: PF-05082566 0.12mg/kg</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion A: PF-05082566 0.18mg/kg</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion A: PF-05082566 0.24mg/kg</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion A: PF-05082566 0.3mg/kg</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion A: PF-05082566 0.6mg/kg</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion A: PF-05082566 1.2mg/kg</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion A: PF-05082566 2.4mg/kg</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion A: PF-05082566 5mg/kg</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O12">
            <title>Portion A: PF-05082566 10mg/kg</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>PF-05082566 Clearance (CL) in Portion A</title>
          <description>CL = Dose/AUCinf for Cycle 1 and Dose/AUCtau for Cycle 2. It was reported in units of milliliter per hour per kilogram (mL/hr/kg).</description>
          <population>All participants who received at least 1 dose of PF-05082566 in Portion A and had at least 1 of the PK parameters of interest. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
          <units>milliliter/hour/kilogram (mL/hr/kg)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="21"/>
                    <count group_id="O10" value="2"/>
                    <count group_id="O11" value="4"/>
                    <count group_id="O12" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.2510" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O3" value="0.3203" spread="31"/>
                    <measurement group_id="O4" value="0.1800" spread="13"/>
                    <measurement group_id="O5" value="0.1823" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O6" value="0.3490" spread="42"/>
                    <measurement group_id="O7" value="0.3890" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O8" value="0.2054" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O9" value="0.3861" spread="36"/>
                    <measurement group_id="O10" value="0.3145" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O11" value="0.2711" spread="24"/>
                    <measurement group_id="O12" value="0.3536" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="4"/>
                    <count group_id="O10" value="1"/>
                    <count group_id="O11" value="5"/>
                    <count group_id="O12" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.2296" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O3" value="0.2676" spread="19"/>
                    <measurement group_id="O4" value="0.1939" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O5" value="0.2082" spread="47"/>
                    <measurement group_id="O6" value="0.2906" spread="37"/>
                    <measurement group_id="O7" value="0.1786" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O8" value="0.2847" spread="43"/>
                    <measurement group_id="O9" value="0.2950" spread="27"/>
                    <measurement group_id="O10" value="0.3220" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O11" value="0.2626" spread="18"/>
                    <measurement group_id="O12" value="0.4883" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PF-05082566 Volume of Distribution at Steady State (Vss) in Portion A</title>
        <description>Vss = CL × MRT, where CL is clearance and MRT is the mean residence time after intravenous administration.</description>
        <time_frame>Day 1 of Cycle 1 and Cycle 2 at pre-dose, and 1, 1.5, 2, 6, 24, 48, 168, 336 and 504 hours post-dose.</time_frame>
        <population>All participants who received at least 1 dose of PF-05082566 in Portion A and had at least 1 of the PK parameters of interest. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion A: PF-05082566 0.006mg/kg</title>
            <description>Participants received PF-05082566 0.006 milligrams per kilogram (mg/kg) intravenously once every 4 weeks (q4wks) as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion A: PF-05082566 0.03mg/kg</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion A: PF-05082566 0.06mg/kg</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion A: PF-05082566 0.12mg/kg</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion A: PF-05082566 0.18mg/kg</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion A: PF-05082566 0.24mg/kg</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion A: PF-05082566 0.3mg/kg</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion A: PF-05082566 0.6mg/kg</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion A: PF-05082566 1.2mg/kg</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion A: PF-05082566 2.4mg/kg</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion A: PF-05082566 5mg/kg</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O12">
            <title>Portion A: PF-05082566 10mg/kg</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>PF-05082566 Volume of Distribution at Steady State (Vss) in Portion A</title>
          <description>Vss = CL × MRT, where CL is clearance and MRT is the mean residence time after intravenous administration.</description>
          <population>All participants who received at least 1 dose of PF-05082566 in Portion A and had at least 1 of the PK parameters of interest. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
          <units>milliliter per kilogram (mL/kg)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="21"/>
                    <count group_id="O10" value="2"/>
                    <count group_id="O11" value="4"/>
                    <count group_id="O12" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="65.50" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O3" value="101.1" spread="20"/>
                    <measurement group_id="O4" value="83.63" spread="15"/>
                    <measurement group_id="O5" value="74.38" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O6" value="110.7" spread="28"/>
                    <measurement group_id="O7" value="75.20" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O8" value="82.38" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O9" value="112.2" spread="29"/>
                    <measurement group_id="O10" value="110.4" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O11" value="97.07" spread="26"/>
                    <measurement group_id="O12" value="125.5" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="1"/>
                    <count group_id="O11" value="3"/>
                    <count group_id="O12" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="102.1" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O3" value="74.11" spread="21"/>
                    <measurement group_id="O4" value="90.80" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O5" value="81.69" spread="27"/>
                    <measurement group_id="O6" value="86.50" spread="29"/>
                    <measurement group_id="O7" value="51.00" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O8" value="61.54" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O9" value="116.5" spread="62"/>
                    <measurement group_id="O10" value="99.80" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O11" value="87.37" spread="43"/>
                    <measurement group_id="O12" value="139.5" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Positive Anti-Drug Antibody (ADA) for PF-05082566 in Portion A</title>
        <description>ADA for PF-05082566 was detected using electrochemiluminescence assay. Positive ADA for PF-05082566: titer&gt;=6.23.</description>
        <time_frame>Up to approximately 2 years</time_frame>
        <population>All participants who received at least 1 dose of PF-05082566 in Portion A and was tested for ADA.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion A: PF-05082566 0.006mg/kg</title>
            <description>Participants received PF-05082566 0.006 milligrams per kilogram (mg/kg) intravenously once every 4 weeks (q4wks) as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion A: PF-05082566 0.03mg/kg</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion A: PF-05082566 0.06mg/kg</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion A: PF-05082566 0.12mg/kg</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion A: PF-05082566 0.18mg/kg</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion A: PF-05082566 0.24mg/kg</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion A: PF-05082566 0.3mg/kg</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion A: PF-05082566 0.6mg/kg</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion A: PF-05082566 1.2mg/kg</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion A: PF-05082566 2.4mg/kg</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion A: PF-05082566 5mg/kg</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O12">
            <title>Portion A: PF-05082566 10mg/kg</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive Anti-Drug Antibody (ADA) for PF-05082566 in Portion A</title>
          <description>ADA for PF-05082566 was detected using electrochemiluminescence assay. Positive ADA for PF-05082566: titer&gt;=6.23.</description>
          <population>All participants who received at least 1 dose of PF-05082566 in Portion A and was tested for ADA.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="31"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="20"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="14"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With QTc Interval Meeting Categorical Summarization Criteria in Portion A</title>
        <description>Categorical summarization criteria for QTc interval (time from ECG Q wave to the end of the T wave corresponding to electrical systole corrected for heart rate): 1) absolute value of &gt;450 to &lt;=480 milliseconds (msec), &gt;480 to &lt;=500 msec, &gt;500 msec; 2) a maximum change from baseline of &gt;30 to &lt;=60 msec or &gt;60 msec.</description>
        <time_frame>Up to approximately 2 years</time_frame>
        <population>All participants who received at least 1 dose of PF-05082566 in Portion A and had post-baseline QTc data. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion A: PF-05082566 0.006mg/kg</title>
            <description>Participants received PF-05082566 0.006 milligrams per kilogram (mg/kg) intravenously once every 4 weeks (q4wks) as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion A: PF-05082566 0.03mg/kg</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion A: PF-05082566 0.06mg/kg</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion A: PF-05082566 0.12mg/kg</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion A: PF-05082566 0.18mg/kg</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion A: PF-05082566 0.24mg/kg</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion A: PF-05082566 0.3mg/kg</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion A: PF-05082566 0.6mg/kg</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion A: PF-05082566 1.2mg/kg</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion A: PF-05082566 2.4mg/kg</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion A: PF-05082566 5mg/kg</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O12">
            <title>Portion A: PF-05082566 10mg/kg</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With QTc Interval Meeting Categorical Summarization Criteria in Portion A</title>
          <description>Categorical summarization criteria for QTc interval (time from ECG Q wave to the end of the T wave corresponding to electrical systole corrected for heart rate): 1) absolute value of &gt;450 to &lt;=480 milliseconds (msec), &gt;480 to &lt;=500 msec, &gt;500 msec; 2) a maximum change from baseline of &gt;30 to &lt;=60 msec or &gt;60 msec.</description>
          <population>All participants who received at least 1 dose of PF-05082566 in Portion A and had post-baseline QTc data. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>QTc &gt;450 to &lt;=480 msec</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="29"/>
                    <count group_id="O10" value="5"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="8"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc &gt;480 to &lt;=500 msec</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="29"/>
                    <count group_id="O10" value="5"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc &gt;500 msec</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="29"/>
                    <count group_id="O10" value="5"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc change &gt;30 to &lt;=60 msec</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="39"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="29"/>
                    <count group_id="O10" value="5"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc change &gt;60 msec</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="39"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="29"/>
                    <count group_id="O10" value="5"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Objective Response Per Response Evaluation Criteria in Solid Tumor (RECIST) Version 1.1 in Portion A</title>
        <description>Objective response: confirmed best overall response (BOR) of complete response (CR) or partial response (PR) per RECIST version 1.1. BOR of CR: target lesions and non-target diseases achieved CR, without new lesions. BOR of PR: target lesions achieved CR or PR while non-target diseases were non-CR/non-progression of disease (non-PD), indeterminate or missing, and without new lesions. For target lesions, CR: complete disappearance of all target lesions except nodal disease (target nodes must decrease to normal size); PR: &gt;=30% decrease under baseline of the sum of diameters of all target measurable lesions. For non-target diseases, CR: disappearance of all non-target lesions and normalization of tumor marker levels; non-CR/non-PD: persistence of any non-target lesions and/or tumor marker level above the normal limits; Indeterminate: progression had not been determined and &gt;=1 non-target sites were not assessed or assessment methods were inconsistent with those used at baseline.</description>
        <time_frame>Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)</time_frame>
        <population>All participants who received at least 1 dose of PF-05082566 in Portion A and had tumor assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion A: PF-05082566 0.006mg/kg</title>
            <description>Participants received PF-05082566 0.006 milligrams per kilogram (mg/kg) intravenously once every 4 weeks (q4wks) as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion A: PF-05082566 0.03mg/kg</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion A: PF-05082566 0.06mg/kg</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion A: PF-05082566 0.12mg/kg</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion A: PF-05082566 0.18mg/kg</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion A: PF-05082566 0.24mg/kg</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion A: PF-05082566 0.3mg/kg</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion A: PF-05082566 0.6mg/kg</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion A: PF-05082566 1.2mg/kg</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion A: PF-05082566 2.4mg/kg</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion A: PF-05082566 5mg/kg</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O12">
            <title>Portion A: PF-05082566 10mg/kg</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Objective Response Per Response Evaluation Criteria in Solid Tumor (RECIST) Version 1.1 in Portion A</title>
          <description>Objective response: confirmed best overall response (BOR) of complete response (CR) or partial response (PR) per RECIST version 1.1. BOR of CR: target lesions and non-target diseases achieved CR, without new lesions. BOR of PR: target lesions achieved CR or PR while non-target diseases were non-CR/non-progression of disease (non-PD), indeterminate or missing, and without new lesions. For target lesions, CR: complete disappearance of all target lesions except nodal disease (target nodes must decrease to normal size); PR: &gt;=30% decrease under baseline of the sum of diameters of all target measurable lesions. For non-target diseases, CR: disappearance of all non-target lesions and normalization of tumor marker levels; non-CR/non-PD: persistence of any non-target lesions and/or tumor marker level above the normal limits; Indeterminate: progression had not been determined and &gt;=1 non-target sites were not assessed or assessment methods were inconsistent with those used at baseline.</description>
          <population>All participants who received at least 1 dose of PF-05082566 in Portion A and had tumor assessments.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="31"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="60.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="70.8"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="45.9"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="60.2"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="97.5"/>
                    <measurement group_id="O6" value="4.8" lower_limit="0.6" upper_limit="16.2"/>
                    <measurement group_id="O7" value="0" lower_limit="0" upper_limit="70.8"/>
                    <measurement group_id="O8" value="25.0" lower_limit="0.6" upper_limit="80.6"/>
                    <measurement group_id="O9" value="0" lower_limit="0" upper_limit="11.2"/>
                    <measurement group_id="O10" value="0" lower_limit="0" upper_limit="52.2"/>
                    <measurement group_id="O11" value="0" lower_limit="0" upper_limit="45.9"/>
                    <measurement group_id="O12" value="0" lower_limit="0" upper_limit="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response in Portion A</title>
        <description>Duration of response: the time from first documentation of objective response (confirmed BOR of CR or PR per RECIST version 1.1) to the date of first documentation of objective progression of disease (PD) or death due to any cause. Objective PD per RECIST version 1.1: &gt;=20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 millimeters (mm); or unequivocal progression of pre-existing lesions for non-target disease; or appearance of new lesions. This outcome measure reports the individual values for evaluable participants (instead of medians etc) due to the limited number of events.</description>
        <time_frame>Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)</time_frame>
        <population>All participants who received at least 1 dose of PF-05082566 in Portion A and achieved an objective response. &quot;Number analyzed&quot; represents the number of such participants for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion A: PF-05082566 0.006mg/kg</title>
            <description>Participants received PF-05082566 0.006 milligrams per kilogram (mg/kg) intravenously once every 4 weeks (q4wks) as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion A: PF-05082566 0.03mg/kg</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion A: PF-05082566 0.06mg/kg</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion A: PF-05082566 0.12mg/kg</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion A: PF-05082566 0.18mg/kg</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion A: PF-05082566 0.24mg/kg</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion A: PF-05082566 0.3mg/kg</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion A: PF-05082566 0.6mg/kg</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion A: PF-05082566 1.2mg/kg</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion A: PF-05082566 2.4mg/kg</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion A: PF-05082566 5mg/kg</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O12">
            <title>Portion A: PF-05082566 10mg/kg</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response in Portion A</title>
          <description>Duration of response: the time from first documentation of objective response (confirmed BOR of CR or PR per RECIST version 1.1) to the date of first documentation of objective progression of disease (PD) or death due to any cause. Objective PD per RECIST version 1.1: &gt;=20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 millimeters (mm); or unequivocal progression of pre-existing lesions for non-target disease; or appearance of new lesions. This outcome measure reports the individual values for evaluable participants (instead of medians etc) due to the limited number of events.</description>
          <population>All participants who received at least 1 dose of PF-05082566 in Portion A and achieved an objective response. &quot;Number analyzed&quot; represents the number of such participants for each specified category.</population>
          <units>months</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="1"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>For Participant X in 0.24 mg/kg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>For Participant Y in 0.24 mg/kg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>For Participant Z in 0.6 mg/kg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="0"/>
                    <count group_id="O12" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O8" value="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Response in Portion A</title>
        <description>Time to response: the time from Cycle 1 Day 1 to the first documentation of objective response (confirmed BOR of CR or PR per RECIST version 1.1). BOR of CR: target lesions and non-target diseases achieved CR, without new lesions. BOR of PR: target lesions achieved CR or PR while non-target diseases were non-CR/non-PD, indeterminate or missing, and without new lesions. For target lesions, CR: complete disappearance of all target lesions except nodal disease (target nodes decreased to normal size); PR: &gt;=30% decrease under baseline of the sum of diameters of all target measurable lesions. For non-target diseases, CR: disappearance of all non-target lesions and normalization of tumor marker levels; non-CR/non-PD: persistence of any non-target lesions and/or tumor marker level above the normal limits; Indeterminate: progression had not been determined and &gt;=1 non-target sites were not assessed or assessment methods were inconsistent with those used at baseline.</description>
        <time_frame>Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)</time_frame>
        <population>All participants who received at least 1 dose of PF-05082566 in Portion A and and achieved an objective response.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion A: PF-05082566 0.006mg/kg</title>
            <description>Participants received PF-05082566 0.006 milligrams per kilogram (mg/kg) intravenously once every 4 weeks (q4wks) as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion A: PF-05082566 0.03mg/kg</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion A: PF-05082566 0.06mg/kg</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion A: PF-05082566 0.12mg/kg</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion A: PF-05082566 0.18mg/kg</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion A: PF-05082566 0.24mg/kg</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion A: PF-05082566 0.3mg/kg</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion A: PF-05082566 0.6mg/kg</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion A: PF-05082566 1.2mg/kg</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion A: PF-05082566 2.4mg/kg</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion A: PF-05082566 5mg/kg</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O12">
            <title>Portion A: PF-05082566 10mg/kg</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Response in Portion A</title>
          <description>Time to response: the time from Cycle 1 Day 1 to the first documentation of objective response (confirmed BOR of CR or PR per RECIST version 1.1). BOR of CR: target lesions and non-target diseases achieved CR, without new lesions. BOR of PR: target lesions achieved CR or PR while non-target diseases were non-CR/non-PD, indeterminate or missing, and without new lesions. For target lesions, CR: complete disappearance of all target lesions except nodal disease (target nodes decreased to normal size); PR: &gt;=30% decrease under baseline of the sum of diameters of all target measurable lesions. For non-target diseases, CR: disappearance of all non-target lesions and normalization of tumor marker levels; non-CR/non-PD: persistence of any non-target lesions and/or tumor marker level above the normal limits; Indeterminate: progression had not been determined and &gt;=1 non-target sites were not assessed or assessment methods were inconsistent with those used at baseline.</description>
          <population>All participants who received at least 1 dose of PF-05082566 in Portion A and and achieved an objective response.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="2"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="1"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="10.3" lower_limit="2.3" upper_limit="18.4"/>
                    <measurement group_id="O8" value="1.8" lower_limit="1.8" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-Free Survival in Portion A</title>
        <description>Progression-free survival: the time from Cycle 1 Day 1 to the date of the first documentation of objective PD or death due to any cause, whichever occurred first. Objective PD per RECIST version 1.1: &gt;=20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm; or unequivocal progression of pre-existing lesions for non-target disease; or appearance of new lesions.</description>
        <time_frame>Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)</time_frame>
        <population>All participants who received at least 1 dose of PF-05082566 in Portion A and had tumor assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion A: PF-05082566 0.006mg/kg</title>
            <description>Participants received PF-05082566 0.006 milligrams per kilogram (mg/kg) intravenously once every 4 weeks (q4wks) as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion A: PF-05082566 0.03mg/kg</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion A: PF-05082566 0.06mg/kg</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion A: PF-05082566 0.12mg/kg</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion A: PF-05082566 0.18mg/kg</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion A: PF-05082566 0.24mg/kg</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion A: PF-05082566 0.3mg/kg</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion A: PF-05082566 0.6mg/kg</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion A: PF-05082566 1.2mg/kg</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion A: PF-05082566 2.4mg/kg</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion A: PF-05082566 5mg/kg</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O12">
            <title>Portion A: PF-05082566 10mg/kg</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival in Portion A</title>
          <description>Progression-free survival: the time from Cycle 1 Day 1 to the date of the first documentation of objective PD or death due to any cause, whichever occurred first. Objective PD per RECIST version 1.1: &gt;=20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm; or unequivocal progression of pre-existing lesions for non-target disease; or appearance of new lesions.</description>
          <population>All participants who received at least 1 dose of PF-05082566 in Portion A and had tumor assessments.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="31"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.1" upper_limit="1.8"/>
                    <measurement group_id="O2" value="3.6" lower_limit="1.7" upper_limit="5.5"/>
                    <measurement group_id="O3" value="1.7" lower_limit="1.6" upper_limit="2.1"/>
                    <measurement group_id="O4" value="3.5" lower_limit="1.6" upper_limit="NA">The upper limit of 95% confidence interval (CI) was not estimable due to the small number of events.</measurement>
                    <measurement group_id="O5" value="1.7" lower_limit="NA" upper_limit="NA">95% CI was not estimable due to the small number of events.</measurement>
                    <measurement group_id="O6" value="2.1" lower_limit="1.8" upper_limit="3.7"/>
                    <measurement group_id="O7" value="1.6" lower_limit="1.6" upper_limit="1.6"/>
                    <measurement group_id="O8" value="3.5" lower_limit="1.4" upper_limit="NA">The upper limit of 95% CI was not estimable due to the small number of events.</measurement>
                    <measurement group_id="O9" value="1.7" lower_limit="1.5" upper_limit="1.8"/>
                    <measurement group_id="O10" value="1.1" lower_limit="0.2" upper_limit="1.7"/>
                    <measurement group_id="O11" value="3.3" lower_limit="0.3" upper_limit="NA">The upper limit of 95% CI was not estimable due to the small number of events.</measurement>
                    <measurement group_id="O12" value="1.8" lower_limit="0.9" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival in Portion A</title>
        <description>Overall survival was defined as the time from Cycle 1 Day 1 to the date of death due to any cause.</description>
        <time_frame>Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)</time_frame>
        <population>All participants who received at least 1 dose of PF-05082566 in Portion A and had tumor assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion A: PF-05082566 0.006mg/kg</title>
            <description>Participants received PF-05082566 0.006 milligrams per kilogram (mg/kg) intravenously once every 4 weeks (q4wks) as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion A: PF-05082566 0.03mg/kg</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion A: PF-05082566 0.06mg/kg</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion A: PF-05082566 0.12mg/kg</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion A: PF-05082566 0.18mg/kg</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion A: PF-05082566 0.24mg/kg</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion A: PF-05082566 0.3mg/kg</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion A: PF-05082566 0.6mg/kg</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion A: PF-05082566 1.2mg/kg</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion A: PF-05082566 2.4mg/kg</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion A: PF-05082566 5mg/kg</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O12">
            <title>Portion A: PF-05082566 10mg/kg</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival in Portion A</title>
          <description>Overall survival was defined as the time from Cycle 1 Day 1 to the date of death due to any cause.</description>
          <population>All participants who received at least 1 dose of PF-05082566 in Portion A and had tumor assessments.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="42"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="31"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="2.1" upper_limit="6.2"/>
                    <measurement group_id="O2" value="4.0" lower_limit="3.6" upper_limit="29.7"/>
                    <measurement group_id="O3" value="7.6" lower_limit="4.2" upper_limit="NA">Not estimable due to the small number of events.</measurement>
                    <measurement group_id="O4" value="13.3" lower_limit="5.9" upper_limit="24.1"/>
                    <measurement group_id="O5" value="5.9" lower_limit="NA" upper_limit="NA">Not estimable due to the small number of events.</measurement>
                    <measurement group_id="O6" value="9.0" lower_limit="5.8" upper_limit="16.4"/>
                    <measurement group_id="O7" value="24.5" lower_limit="1.6" upper_limit="NA">Not estimable due to the small number of events.</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="3.9" upper_limit="NA">Not estimable due to the small number of events.</measurement>
                    <measurement group_id="O9" value="7.6" lower_limit="2.9" upper_limit="12.7"/>
                    <measurement group_id="O10" value="11.2" lower_limit="3.7" upper_limit="NA">Not estimable due to the small number of events.</measurement>
                    <measurement group_id="O11" value="29.5" lower_limit="1.8" upper_limit="NA">Not estimable due to the small number of events.</measurement>
                    <measurement group_id="O12" value="6.1" lower_limit="3.9" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent AEs and SAEs in Portion B</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of dying); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. AEs included both non-serious AEs and SAEs. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study treatment. Causality of AEs was determined by the investigator.</description>
        <time_frame>Up to approximately 4 years</time_frame>
        <population>All participants who received at least 1 dose of study treatment (PF-05082566 and/or rituximab) in Portion B.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion B: PF-05082566 0.03mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks in combination with rituximab (375 milligrams per square meter [mg/m^2] intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion B: PF-05082566 0.06mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion B: PF-05082566 0.12mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion B: PF-05082566 0.18mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion B: PF-05082566 0.24mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion B: PF-05082566 0.3mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion B: PF-05082566 0.6mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion B: PF-05082566 1.2mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion B: PF-05082566 2.4mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion B: PF-05082566 5mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion B: PF-05082566 10mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent AEs and SAEs in Portion B</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of dying); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. AEs included both non-serious AEs and SAEs. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study treatment. Causality of AEs was determined by the investigator.</description>
          <population>All participants who received at least 1 dose of study treatment (PF-05082566 and/or rituximab) in Portion B.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="30"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs related to PF-05082566</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="17"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs related to PF-05082566</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs related to rituximab</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="17"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs related to rituximab</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent AEs by Maximum NCI CTCAE Grade in Portion B</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study treatment. Severity of AEs were graded according to NCI CTCAE version 4.03 (Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE).</description>
        <time_frame>Up to approximately 4 years</time_frame>
        <population>All participants who received at least 1 dose of study treatment (PF-05082566 and/or rituximab) in Portion B.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion B: PF-05082566 0.03mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks in combination with rituximab (375 milligrams per square meter [mg/m^2] intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion B: PF-05082566 0.06mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion B: PF-05082566 0.12mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion B: PF-05082566 0.18mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion B: PF-05082566 0.24mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion B: PF-05082566 0.3mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion B: PF-05082566 0.6mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion B: PF-05082566 1.2mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion B: PF-05082566 2.4mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion B: PF-05082566 5mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion B: PF-05082566 10mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent AEs by Maximum NCI CTCAE Grade in Portion B</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study treatment. Severity of AEs were graded according to NCI CTCAE version 4.03 (Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE).</description>
          <population>All participants who received at least 1 dose of study treatment (PF-05082566 and/or rituximab) in Portion B.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="17"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hematology Laboratory Abnormalities by Maximum NCI CTCAE Grade in Portion B</title>
        <description>Following hematology laboratory abnormalities were graded per NCI CTCAE version 4.03: anemia, hemoglobin increased, lymphocyte count increased, lymphopenia, neutrophils (absolute), platelets, white blood cells. The abnormalities with at least 1 participant are presented here.</description>
        <time_frame>Up to approximately 2 years</time_frame>
        <population>All participants who received at least 1 dose of study treatment (PF-05082566 and/or rituximab) in Portion B and had hematology laboratory test data.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion B: PF-05082566 0.03mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks in combination with rituximab (375 milligrams per square meter [mg/m^2] intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion B: PF-05082566 0.06mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion B: PF-05082566 0.12mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion B: PF-05082566 0.18mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion B: PF-05082566 0.24mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion B: PF-05082566 0.3mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion B: PF-05082566 0.6mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion B: PF-05082566 1.2mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion B: PF-05082566 2.4mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion B: PF-05082566 5mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion B: PF-05082566 10mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hematology Laboratory Abnormalities by Maximum NCI CTCAE Grade in Portion B</title>
          <description>Following hematology laboratory abnormalities were graded per NCI CTCAE version 4.03: anemia, hemoglobin increased, lymphocyte count increased, lymphopenia, neutrophils (absolute), platelets, white blood cells. The abnormalities with at least 1 participant are presented here.</description>
          <population>All participants who received at least 1 dose of study treatment (PF-05082566 and/or rituximab) in Portion B and had hematology laboratory test data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anemia, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="16"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anemia, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin increased, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocyte count increased, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphopenia, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphopenia, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphopenia, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (absolute), Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (absolute), Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (absolute), Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (absolute), Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="11"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cells, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="11"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cells, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White blood cells, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Chemistries Laboratory Abnormalities by Maximum NCI CTCAE Grade in Portion B</title>
        <description>Following chemistries laboratory abnormalities were graded per NCI CTCAE version 4.03: alanine aminotransferase (ALT), Alkaline phosphatase, Aspartate aminotransferase (AST), bilirubin (total), creatinine, gamma glutamyl transferase (GGT), hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia. The abnormalities with at least 1 participant are presented here.</description>
        <time_frame>Up to approximately 2 years</time_frame>
        <population>All participants who received at least 1 dose of study treatment (PF-05082566 and/or rituximab) in Portion B and had chemistries laboratory test data.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion B: PF-05082566 0.03mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks in combination with rituximab (375 milligrams per square meter [mg/m^2] intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion B: PF-05082566 0.06mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion B: PF-05082566 0.12mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion B: PF-05082566 0.18mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion B: PF-05082566 0.24mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion B: PF-05082566 0.3mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion B: PF-05082566 0.6mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion B: PF-05082566 1.2mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion B: PF-05082566 2.4mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion B: PF-05082566 5mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion B: PF-05082566 10mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Chemistries Laboratory Abnormalities by Maximum NCI CTCAE Grade in Portion B</title>
          <description>Following chemistries laboratory abnormalities were graded per NCI CTCAE version 4.03: alanine aminotransferase (ALT), Alkaline phosphatase, Aspartate aminotransferase (AST), bilirubin (total), creatinine, gamma glutamyl transferase (GGT), hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia. The abnormalities with at least 1 participant are presented here.</description>
          <population>All participants who received at least 1 dose of study treatment (PF-05082566 and/or rituximab) in Portion B and had chemistries laboratory test data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin (total), Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin (total), Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="27"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypercalcemia, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperglycemia, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperglycemia, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperglycemia, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperkalemia, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperkalemia, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperkalemia, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypermagnesemia, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypermagnesemia, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypernatremia, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypernatremia, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoalbuminemia, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoalbuminemia, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypocalcemia, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="10"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypocalcemia, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypocalcemia, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypokalemia, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypomagnesemia, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyponatremia, Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyponatremia, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypophosphatemia, Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypophosphatemia, Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Vital Sign Abnormalities in Portion B</title>
        <description>For vital signs in Portion B, blood pressure, pulse rate, and body temperature were measured. Clinical significance was determined by the investigator.</description>
        <time_frame>Up to approximately 2 years</time_frame>
        <population>All participants who received at least 1 dose of study treatment (PF-05082566 and/or rituximab) in Portion B.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion B: PF-05082566 0.03mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks in combination with rituximab (375 milligrams per square meter [mg/m^2] intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion B: PF-05082566 0.06mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion B: PF-05082566 0.12mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion B: PF-05082566 0.18mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion B: PF-05082566 0.24mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion B: PF-05082566 0.3mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion B: PF-05082566 0.6mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion B: PF-05082566 1.2mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion B: PF-05082566 2.4mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion B: PF-05082566 5mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion B: PF-05082566 10mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Vital Sign Abnormalities in Portion B</title>
          <description>For vital signs in Portion B, blood pressure, pulse rate, and body temperature were measured. Clinical significance was determined by the investigator.</description>
          <population>All participants who received at least 1 dose of study treatment (PF-05082566 and/or rituximab) in Portion B.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PF-05082566 Cmax in Portion B</title>
        <description>Cmax of PF-05082566 was observed directly from data.</description>
        <time_frame>Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.</time_frame>
        <population>All participants who received at least 1 dose of PF-05082566 in Portion B and had at least 1 of the PK parameters of interest. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion B: PF-05082566 0.03mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks in combination with rituximab (375 milligrams per square meter [mg/m^2] intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion B: PF-05082566 0.06mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion B: PF-05082566 0.12mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion B: PF-05082566 0.18mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion B: PF-05082566 0.24mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion B: PF-05082566 0.3mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion B: PF-05082566 0.6mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion B: PF-05082566 1.2mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion B: PF-05082566 2.4mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion B: PF-05082566 5mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion B: PF-05082566 10mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>PF-05082566 Cmax in Portion B</title>
          <description>Cmax of PF-05082566 was observed directly from data.</description>
          <population>All participants who received at least 1 dose of PF-05082566 in Portion B and had at least 1 of the PK parameters of interest. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="30"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="5"/>
                    <count group_id="O11" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6284" spread="11"/>
                    <measurement group_id="O2" value="1.569" spread="12"/>
                    <measurement group_id="O3" value="2.673" spread="26"/>
                    <measurement group_id="O4" value="4.167" spread="12"/>
                    <measurement group_id="O5" value="4.512" spread="29"/>
                    <measurement group_id="O6" value="7.435" spread="9"/>
                    <measurement group_id="O7" value="12.16" spread="9"/>
                    <measurement group_id="O8" value="19.20" spread="27"/>
                    <measurement group_id="O9" value="42.61" spread="26"/>
                    <measurement group_id="O10" value="89.06" spread="23"/>
                    <measurement group_id="O11" value="196.2" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="27"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="5"/>
                    <count group_id="O11" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6838" spread="18"/>
                    <measurement group_id="O2" value="1.948" spread="6"/>
                    <measurement group_id="O3" value="3.102" spread="18"/>
                    <measurement group_id="O4" value="3.934" spread="28"/>
                    <measurement group_id="O5" value="4.607" spread="30"/>
                    <measurement group_id="O6" value="6.481" spread="10"/>
                    <measurement group_id="O7" value="13.97" spread="24"/>
                    <measurement group_id="O8" value="20.03" spread="32"/>
                    <measurement group_id="O9" value="44.35" spread="19"/>
                    <measurement group_id="O10" value="95.16" spread="19"/>
                    <measurement group_id="O11" value="206.0" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PF-05082566 Ctrough in Portion B</title>
        <description>Ctrough of PF-05082566 was observed directly from data.</description>
        <time_frame>Day 1 pre-dose of Cycle 2</time_frame>
        <population>All participants who received at least 1 dose of PF-05082566 in Portion B and had data for Ctrough.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion B: PF-05082566 0.03mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks in combination with rituximab (375 milligrams per square meter [mg/m^2] intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion B: PF-05082566 0.06mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion B: PF-05082566 0.12mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion B: PF-05082566 0.18mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion B: PF-05082566 0.24mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion B: PF-05082566 0.3mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion B: PF-05082566 0.6mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion B: PF-05082566 1.2mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion B: PF-05082566 2.4mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion B: PF-05082566 5mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion B: PF-05082566 10mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>PF-05082566 Ctrough in Portion B</title>
          <description>Ctrough of PF-05082566 was observed directly from data.</description>
          <population>All participants who received at least 1 dose of PF-05082566 in Portion B and had data for Ctrough.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="27"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1267" spread="47"/>
                    <measurement group_id="O2" value="0.2853" spread="23"/>
                    <measurement group_id="O3" value="0.3922" spread="29"/>
                    <measurement group_id="O4" value="0.4698" spread="53"/>
                    <measurement group_id="O5" value="0.3539" spread="110"/>
                    <measurement group_id="O6" value="0.6001" spread="48"/>
                    <measurement group_id="O7" value="1.486" spread="90"/>
                    <measurement group_id="O8" value="1.452" spread="62"/>
                    <measurement group_id="O9" value="5.560" spread="29"/>
                    <measurement group_id="O10" value="12.16" spread="63"/>
                    <measurement group_id="O11" value="31.34" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PF-05082566 Tmax in Portion B</title>
        <description>Tmax of PF-05082566 was observed directly from data as time of Cmax.</description>
        <time_frame>Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.</time_frame>
        <population>All participants who received at least 1 dose of PF-05082566 in Portion B and had at least 1 of the PK parameters of interest. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion B: PF-05082566 0.03mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks in combination with rituximab (375 milligrams per square meter [mg/m^2] intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion B: PF-05082566 0.06mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion B: PF-05082566 0.12mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion B: PF-05082566 0.18mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion B: PF-05082566 0.24mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion B: PF-05082566 0.3mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion B: PF-05082566 0.6mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion B: PF-05082566 1.2mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion B: PF-05082566 2.4mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion B: PF-05082566 5mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion B: PF-05082566 10mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>PF-05082566 Tmax in Portion B</title>
          <description>Tmax of PF-05082566 was observed directly from data as time of Cmax.</description>
          <population>All participants who received at least 1 dose of PF-05082566 in Portion B and had at least 1 of the PK parameters of interest. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="30"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="30"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="5"/>
                    <count group_id="O11" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="1.28" upper_limit="2.00"/>
                    <measurement group_id="O2" value="1.52" lower_limit="1.00" upper_limit="1.83"/>
                    <measurement group_id="O3" value="1.06" lower_limit="0.950" upper_limit="1.42"/>
                    <measurement group_id="O4" value="2.00" lower_limit="1.50" upper_limit="2.00"/>
                    <measurement group_id="O5" value="1.52" lower_limit="1.02" upper_limit="1.63"/>
                    <measurement group_id="O6" value="1.17" lower_limit="1.00" upper_limit="1.52"/>
                    <measurement group_id="O7" value="2.00" lower_limit="1.00" upper_limit="6.07"/>
                    <measurement group_id="O8" value="1.06" lower_limit="0.933" upper_limit="5.45"/>
                    <measurement group_id="O9" value="2.00" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O10" value="2.00" lower_limit="1.50" upper_limit="6.00"/>
                    <measurement group_id="O11" value="2.00" lower_limit="1.00" upper_limit="6.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="27"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="5"/>
                    <count group_id="O11" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" lower_limit="1.00" upper_limit="1.05"/>
                    <measurement group_id="O2" value="1.08" lower_limit="1.00" upper_limit="1.55"/>
                    <measurement group_id="O3" value="1.04" lower_limit="1.03" upper_limit="1.08"/>
                    <measurement group_id="O4" value="1.57" lower_limit="1.07" upper_limit="21.1"/>
                    <measurement group_id="O5" value="1.00" lower_limit="0.967" upper_limit="1.10"/>
                    <measurement group_id="O6" value="1.50" lower_limit="0.967" upper_limit="1.50"/>
                    <measurement group_id="O7" value="1.33" lower_limit="1.17" upper_limit="1.50"/>
                    <measurement group_id="O8" value="1.02" lower_limit="0.967" upper_limit="1.98"/>
                    <measurement group_id="O9" value="1.50" lower_limit="1.50" upper_limit="1.55"/>
                    <measurement group_id="O10" value="1.50" lower_limit="1.00" upper_limit="1.50"/>
                    <measurement group_id="O11" value="1.28" lower_limit="1.00" upper_limit="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PF-05082566 AUClast in Portion B</title>
        <description>AUClast of PF-05082566 was determined by linear/log trapezoidal method.</description>
        <time_frame>Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.</time_frame>
        <population>All participants who received at least 1 dose of PF-05082566 in Portion B and had at least 1 of the PK parameters of interest. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion B: PF-05082566 0.03mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks in combination with rituximab (375 milligrams per square meter [mg/m^2] intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion B: PF-05082566 0.06mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion B: PF-05082566 0.12mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion B: PF-05082566 0.18mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion B: PF-05082566 0.24mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion B: PF-05082566 0.3mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion B: PF-05082566 0.6mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion B: PF-05082566 1.2mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion B: PF-05082566 2.4mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion B: PF-05082566 5mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion B: PF-05082566 10mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>PF-05082566 AUClast in Portion B</title>
          <description>AUClast of PF-05082566 was determined by linear/log trapezoidal method.</description>
          <population>All participants who received at least 1 dose of PF-05082566 in Portion B and had at least 1 of the PK parameters of interest. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
          <units>μg*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="30"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="29"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="5"/>
                    <count group_id="O11" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.1" spread="26"/>
                    <measurement group_id="O2" value="342.6" spread="13"/>
                    <measurement group_id="O3" value="513.7" spread="20"/>
                    <measurement group_id="O4" value="854.1" spread="31"/>
                    <measurement group_id="O5" value="701.7" spread="72"/>
                    <measurement group_id="O6" value="1130" spread="14"/>
                    <measurement group_id="O7" value="2373" spread="37"/>
                    <measurement group_id="O8" value="2772" spread="63"/>
                    <measurement group_id="O9" value="7955" spread="30"/>
                    <measurement group_id="O10" value="17120" spread="33"/>
                    <measurement group_id="O11" value="38180" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="5"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="5"/>
                    <count group_id="O11" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176.2" spread="26"/>
                    <measurement group_id="O2" value="471.5" spread="7"/>
                    <measurement group_id="O3" value="696.5" spread="17"/>
                    <measurement group_id="O4" value="1146" spread="35"/>
                    <measurement group_id="O5" value="733.7" spread="85"/>
                    <measurement group_id="O6" value="1511" spread="10"/>
                    <measurement group_id="O7" value="3013" spread="70"/>
                    <measurement group_id="O8" value="6193" spread="22"/>
                    <measurement group_id="O9" value="10970" spread="44"/>
                    <measurement group_id="O10" value="19410" spread="37"/>
                    <measurement group_id="O11" value="48540" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PF-05082566 AUCinf in Portion B</title>
        <description>AUCinf = AUClast + (Clast*/kel), where Clast* is the estimated concentration at the time of the last measurable concentration and kel is the terminal phase rate constant calculated as the absolute value of the slope of a linear regression during the terminal phase of the natural log-transformed concentration time profile.</description>
        <time_frame>Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose.</time_frame>
        <population>All participants who received at least 1 dose of PF-05082566 in Portion B and had AUCinf data.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion B: PF-05082566 0.03mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks in combination with rituximab (375 milligrams per square meter [mg/m^2] intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion B: PF-05082566 0.06mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion B: PF-05082566 0.12mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion B: PF-05082566 0.18mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion B: PF-05082566 0.24mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion B: PF-05082566 0.3mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion B: PF-05082566 0.6mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion B: PF-05082566 1.2mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion B: PF-05082566 2.4mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion B: PF-05082566 5mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion B: PF-05082566 10mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>PF-05082566 AUCinf in Portion B</title>
          <description>AUCinf = AUClast + (Clast*/kel), where Clast* is the estimated concentration at the time of the last measurable concentration and kel is the terminal phase rate constant calculated as the absolute value of the slope of a linear regression during the terminal phase of the natural log-transformed concentration time profile.</description>
          <population>All participants who received at least 1 dose of PF-05082566 in Portion B and had AUCinf data.</population>
          <units>μg*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="23"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="2"/>
                <count group_id="O11" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.8" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O2" value="407.0" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O3" value="615.5" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O4" value="1076" spread="38"/>
                    <measurement group_id="O5" value="824.1" spread="78"/>
                    <measurement group_id="O6" value="1421" spread="24"/>
                    <measurement group_id="O7" value="2070" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O8" value="3703" spread="37"/>
                    <measurement group_id="O9" value="9439" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O10" value="16790" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O11" value="48870" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PF-05082566 AUCtau in Portion B</title>
        <description>AUCtau of PF-05082566 was determined using linear/log trapezoidal method.</description>
        <time_frame>Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.</time_frame>
        <population>All participants who received at least 1 dose of PF-05082566 in Portion B and had at least 1 of the PK parameters of interest. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion B: PF-05082566 0.03mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks in combination with rituximab (375 milligrams per square meter [mg/m^2] intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion B: PF-05082566 0.06mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion B: PF-05082566 0.12mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion B: PF-05082566 0.18mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion B: PF-05082566 0.24mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion B: PF-05082566 0.3mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion B: PF-05082566 0.6mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion B: PF-05082566 1.2mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion B: PF-05082566 2.4mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion B: PF-05082566 5mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion B: PF-05082566 10mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>PF-05082566 AUCtau in Portion B</title>
          <description>AUCtau of PF-05082566 was determined using linear/log trapezoidal method.</description>
          <population>All participants who received at least 1 dose of PF-05082566 in Portion B and had at least 1 of the PK parameters of interest. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
          <units>μg*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="30"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="26"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="5"/>
                    <count group_id="O11" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.0" spread="23"/>
                    <measurement group_id="O2" value="345.0" spread="16"/>
                    <measurement group_id="O3" value="514.5" spread="21"/>
                    <measurement group_id="O4" value="871.6" spread="32"/>
                    <measurement group_id="O5" value="712.0" spread="71"/>
                    <measurement group_id="O6" value="1128" spread="15"/>
                    <measurement group_id="O7" value="2361" spread="39"/>
                    <measurement group_id="O8" value="3206" spread="32"/>
                    <measurement group_id="O9" value="8001" spread="29"/>
                    <measurement group_id="O10" value="17290" spread="32"/>
                    <measurement group_id="O11" value="38860" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178.2" spread="26"/>
                    <measurement group_id="O2" value="453.9" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O3" value="701.8" spread="18"/>
                    <measurement group_id="O4" value="1072" spread="33"/>
                    <measurement group_id="O5" value="854.5" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O6" value="1521" spread="10"/>
                    <measurement group_id="O7" value="3116" spread="63"/>
                    <measurement group_id="O8" value="5967" spread="30"/>
                    <measurement group_id="O9" value="10220" spread="30"/>
                    <measurement group_id="O10" value="18150" spread="39"/>
                    <measurement group_id="O11" value="48030" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PF-05082566 CL in Portion B</title>
        <description>CL = Dose/AUCinf for Cycle 1 and Dose/AUCtau for Cycle 2.</description>
        <time_frame>Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.</time_frame>
        <population>All participants who received at least 1 dose of PF-05082566 in Portion B and had at least 1 of the PK parameters of interest. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion B: PF-05082566 0.03mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks in combination with rituximab (375 milligrams per square meter [mg/m^2] intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion B: PF-05082566 0.06mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion B: PF-05082566 0.12mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion B: PF-05082566 0.18mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion B: PF-05082566 0.24mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion B: PF-05082566 0.3mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion B: PF-05082566 0.6mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion B: PF-05082566 1.2mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion B: PF-05082566 2.4mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion B: PF-05082566 5mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion B: PF-05082566 10mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>PF-05082566 CL in Portion B</title>
          <description>CL = Dose/AUCinf for Cycle 1 and Dose/AUCtau for Cycle 2.</description>
          <population>All participants who received at least 1 dose of PF-05082566 in Portion B and had at least 1 of the PK parameters of interest. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
          <units>mL/hr/kg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="30"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="2"/>
                    <count group_id="O10" value="2"/>
                    <count group_id="O11" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2178" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O2" value="0.1470" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O3" value="0.1950" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O4" value="0.1667" spread="38"/>
                    <measurement group_id="O5" value="0.2911" spread="78"/>
                    <measurement group_id="O6" value="0.2107" spread="24"/>
                    <measurement group_id="O7" value="0.2900" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O8" value="0.3241" spread="37"/>
                    <measurement group_id="O9" value="0.2546" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O10" value="0.2973" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O11" value="0.2048" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="3"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1683" spread="26"/>
                    <measurement group_id="O2" value="0.1325" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O3" value="0.1710" spread="18"/>
                    <measurement group_id="O4" value="0.1681" spread="33"/>
                    <measurement group_id="O5" value="0.2807" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O6" value="0.1976" spread="11"/>
                    <measurement group_id="O7" value="0.1928" spread="63"/>
                    <measurement group_id="O8" value="0.2011" spread="30"/>
                    <measurement group_id="O9" value="0.2351" spread="29"/>
                    <measurement group_id="O10" value="0.2756" spread="39"/>
                    <measurement group_id="O11" value="0.2080" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PF-05082566 Vss in Portion B</title>
        <description>Vss = CL × MRT, where CL is clearance and MRT is the mean residence time after intravenous administration.</description>
        <time_frame>Cycle 1 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 144, 312, and 504 hours post-dose; Cycle 2 Day 1 pre-dose, 1.5, 2, 6, 24, 48, 168, 336, and 504 hours post-dose.</time_frame>
        <population>All participants who received at least 1 dose of PF-05082566 in Portion B and had at least 1 of the PK parameters of interest. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion B: PF-05082566 0.03mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks in combination with rituximab (375 milligrams per square meter [mg/m^2] intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion B: PF-05082566 0.06mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion B: PF-05082566 0.12mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion B: PF-05082566 0.18mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion B: PF-05082566 0.24mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion B: PF-05082566 0.3mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion B: PF-05082566 0.6mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion B: PF-05082566 1.2mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion B: PF-05082566 2.4mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion B: PF-05082566 5mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion B: PF-05082566 10mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>PF-05082566 Vss in Portion B</title>
          <description>Vss = CL × MRT, where CL is clearance and MRT is the mean residence time after intravenous administration.</description>
          <population>All participants who received at least 1 dose of PF-05082566 in Portion B and had at least 1 of the PK parameters of interest. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
          <units>mL/kg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="30"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="23"/>
                    <count group_id="O9" value="2"/>
                    <count group_id="O10" value="2"/>
                    <count group_id="O11" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.87" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O2" value="78.60" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O3" value="79.93" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O4" value="66.90" spread="24"/>
                    <measurement group_id="O5" value="93.68" spread="54"/>
                    <measurement group_id="O6" value="85.12" spread="4"/>
                    <measurement group_id="O7" value="126.0" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O8" value="102.8" spread="20"/>
                    <measurement group_id="O9" value="130.9" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O10" value="98.98" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O11" value="94.08" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="2"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="2"/>
                    <count group_id="O11" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="81.90" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O4" value="65.42" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O5" value="85.51" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O6" value="66.27" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O7" value="100.5" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O8" value="86.99" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O9" value="94.00" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O10" value="102.2" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                    <measurement group_id="O11" value="95.89" spread="NA">Geometric CV was not calculated when there were less than 3 participants with data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rituximab Cmax and Ctrough in Portion B</title>
        <description>Cmax and Ctrough of rituximab were observed directly from data.</description>
        <time_frame>Day 1 pre-dose of Cycle 2</time_frame>
        <population>All participants who received at least 1 dose of rituximab in Portion B and had Cmax or Ctrough data for rituximab. No data were collected for this Outcome Measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion B: PF-05082566 0.03mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks in combination with rituximab (375 milligrams per square meter [mg/m^2] intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion B: PF-05082566 0.06mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion B: PF-05082566 0.12mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion B: PF-05082566 0.18mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion B: PF-05082566 0.24mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion B: PF-05082566 0.3mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion B: PF-05082566 0.6mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion B: PF-05082566 1.2mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion B: PF-05082566 2.4mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion B: PF-05082566 5mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion B: PF-05082566 10mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Rituximab Cmax and Ctrough in Portion B</title>
          <description>Cmax and Ctrough of rituximab were observed directly from data.</description>
          <population>All participants who received at least 1 dose of rituximab in Portion B and had Cmax or Ctrough data for rituximab. No data were collected for this Outcome Measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Positive ADA for PF-05082566 and Rituximab in Portion B</title>
        <description>ADA for PF-05082566 and rituximab was detected using electrochemiluminescence assay. Positive ADA for PF-05082566: titer&gt;=6.23. Positive ADA for rituximab: titer&gt;=1.88.</description>
        <time_frame>Up to approximately 2 years</time_frame>
        <population>All participants who received at least 1 dose of study treatment (PF-05082566 and/or rituximab) in Portion B and was tested for ADA. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion B: PF-05082566 0.03mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks in combination with rituximab (375 milligrams per square meter [mg/m^2] intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion B: PF-05082566 0.06mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion B: PF-05082566 0.12mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion B: PF-05082566 0.18mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion B: PF-05082566 0.24mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion B: PF-05082566 0.3mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion B: PF-05082566 0.6mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion B: PF-05082566 1.2mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion B: PF-05082566 2.4mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion B: PF-05082566 5mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion B: PF-05082566 10mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive ADA for PF-05082566 and Rituximab in Portion B</title>
          <description>ADA for PF-05082566 and rituximab was detected using electrochemiluminescence assay. Positive ADA for PF-05082566: titer&gt;=6.23. Positive ADA for rituximab: titer&gt;=1.88.</description>
          <population>All participants who received at least 1 dose of study treatment (PF-05082566 and/or rituximab) in Portion B and was tested for ADA. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>For PF-05082566</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="32"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="5"/>
                    <count group_id="O11" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>For rituximab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="32"/>
                    <count group_id="O9" value="3"/>
                    <count group_id="O10" value="5"/>
                    <count group_id="O11" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With QTc Interval Meeting Categorical Summarization Criteria in Portion B</title>
        <description>Categorical summarization criteria for QTc interval: 1) absolute value of &gt;450 to &lt;=480 milliseconds (msec), &gt;480 to &lt;=500 msec, &gt;500 msec; 2) a maximum change from baseline of &gt;30 to &lt;=60 msec or &gt;60 msec.</description>
        <time_frame>Up to approximately 2 years</time_frame>
        <population>All participants who received at least 1 dose of study treatment (PF-05082566 and/or rituximab) in Portion B and had post-baseline QTc data. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion B: PF-05082566 0.03mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks in combination with rituximab (375 milligrams per square meter [mg/m^2] intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion B: PF-05082566 0.06mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion B: PF-05082566 0.12mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion B: PF-05082566 0.18mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion B: PF-05082566 0.24mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion B: PF-05082566 0.3mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion B: PF-05082566 0.6mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion B: PF-05082566 1.2mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion B: PF-05082566 2.4mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion B: PF-05082566 5mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion B: PF-05082566 10mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With QTc Interval Meeting Categorical Summarization Criteria in Portion B</title>
          <description>Categorical summarization criteria for QTc interval: 1) absolute value of &gt;450 to &lt;=480 milliseconds (msec), &gt;480 to &lt;=500 msec, &gt;500 msec; 2) a maximum change from baseline of &gt;30 to &lt;=60 msec or &gt;60 msec.</description>
          <population>All participants who received at least 1 dose of study treatment (PF-05082566 and/or rituximab) in Portion B and had post-baseline QTc data. &quot;Number Analyzed&quot; represents those participants who had data for each specified category.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>QTc &gt;450 to &lt;=480 msec</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="32"/>
                    <count group_id="O9" value="2"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="14"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc &gt;480 to &lt;=500 msec</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="32"/>
                    <count group_id="O9" value="2"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc &gt;500 msec</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="32"/>
                    <count group_id="O9" value="2"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc change &gt;30 to &lt;=60 msec</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="31"/>
                    <count group_id="O9" value="2"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc change &gt;60 msec</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="4"/>
                    <count group_id="O8" value="31"/>
                    <count group_id="O9" value="2"/>
                    <count group_id="O10" value="4"/>
                    <count group_id="O11" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Objective Response Per Cheson 2007 Criteria in Portion B</title>
        <description>Objective Response in Portion B was defined as BOR of CR or PR according to Cheson 2007 criteria. BOR of CR or PR per Cheson 2007: CR or PR of index lesions (complete disappearance of all detectable clinical and radiographic evidence of disease, all lymph nodes returned to normal size, spleen and/or liver if enlarged prior to therapy became normal or no longer palpable; or &gt;=50% decrease in the sum of the product diameters [SPD] of up to 6 index lesions, no increase in size of other nodes, liver or spleen), without PD of non-index lesions (ie, without: new nonnodal lesion, new nodal lesion &gt;=15 mm in greatest transverse diameter [GTD], unequivocal progression of existing non index lesions, bone marrow that was negative and is now positive, new circulating lymphoma cells in blood cell count and/or pleural fluid, new circulating blasts in the blood cell count), and without any new lesions.</description>
        <time_frame>Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)</time_frame>
        <population>All participants who received at least 1 dose of study treatment (PF-05082566 and/or rituximab) in Portion B and had tumor assessments for lymphoma.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion B: PF-05082566 0.03mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks in combination with rituximab (375 milligrams per square meter [mg/m^2] intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion B: PF-05082566 0.06mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion B: PF-05082566 0.12mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion B: PF-05082566 0.18mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion B: PF-05082566 0.24mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion B: PF-05082566 0.3mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion B: PF-05082566 0.6mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion B: PF-05082566 1.2mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion B: PF-05082566 2.4mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion B: PF-05082566 5mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion B: PF-05082566 10mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Objective Response Per Cheson 2007 Criteria in Portion B</title>
          <description>Objective Response in Portion B was defined as BOR of CR or PR according to Cheson 2007 criteria. BOR of CR or PR per Cheson 2007: CR or PR of index lesions (complete disappearance of all detectable clinical and radiographic evidence of disease, all lymph nodes returned to normal size, spleen and/or liver if enlarged prior to therapy became normal or no longer palpable; or &gt;=50% decrease in the sum of the product diameters [SPD] of up to 6 index lesions, no increase in size of other nodes, liver or spleen), without PD of non-index lesions (ie, without: new nonnodal lesion, new nodal lesion &gt;=15 mm in greatest transverse diameter [GTD], unequivocal progression of existing non index lesions, bone marrow that was negative and is now positive, new circulating lymphoma cells in blood cell count and/or pleural fluid, new circulating blasts in the blood cell count), and without any new lesions.</description>
          <population>All participants who received at least 1 dose of study treatment (PF-05082566 and/or rituximab) in Portion B and had tumor assessments for lymphoma.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="31"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="0.8" upper_limit="90.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="70.8"/>
                    <measurement group_id="O3" value="25.0" lower_limit="0.6" upper_limit="80.6"/>
                    <measurement group_id="O4" value="66.7" lower_limit="9.4" upper_limit="99.2"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="70.8"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="70.8"/>
                    <measurement group_id="O7" value="0" lower_limit="0" upper_limit="60.2"/>
                    <measurement group_id="O8" value="25.8" lower_limit="11.9" upper_limit="44.6"/>
                    <measurement group_id="O9" value="33.3" lower_limit="0.8" upper_limit="90.6"/>
                    <measurement group_id="O10" value="20.0" lower_limit="0.5" upper_limit="71.6"/>
                    <measurement group_id="O11" value="0" lower_limit="0" upper_limit="60.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response in Portion B</title>
        <description>Duration of Response in Portion B was defined, for participants with an objective response (BOR of CR or PR per Cheson 2007 criteria), as the time from first documentation of objective response to the date of first documentation of objective PD or death due to any cause. Objective PD per Cheson 2007 was defined as: PD of index lesions (&gt;=50% increase in SPD of previously involved sites from nadir), or PD of non-index lesions (new nonnodal lesion, new nodal lesion &gt;=15 mm in GTD, unequivocal progression of existing non index lesions, bone marrow that was negative and is now positive, new circulating lymphoma cells in blood cell count and/or pleural fluid, new circulating blasts in the blood cell count), or appearance of new lesions.</description>
        <time_frame>Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)</time_frame>
        <population>All participants who received at least 1 dose of study treatment (PF-05082566 and/or rituximab) in Portion B, had tumor assessments for lymphoma, and achieved an objective response.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion B: PF-05082566 0.03mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks in combination with rituximab (375 milligrams per square meter [mg/m^2] intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion B: PF-05082566 0.06mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion B: PF-05082566 0.12mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion B: PF-05082566 0.18mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion B: PF-05082566 0.24mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion B: PF-05082566 0.3mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion B: PF-05082566 0.6mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion B: PF-05082566 1.2mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion B: PF-05082566 2.4mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion B: PF-05082566 5mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion B: PF-05082566 10mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response in Portion B</title>
          <description>Duration of Response in Portion B was defined, for participants with an objective response (BOR of CR or PR per Cheson 2007 criteria), as the time from first documentation of objective response to the date of first documentation of objective PD or death due to any cause. Objective PD per Cheson 2007 was defined as: PD of index lesions (&gt;=50% increase in SPD of previously involved sites from nadir), or PD of non-index lesions (new nonnodal lesion, new nodal lesion &gt;=15 mm in GTD, unequivocal progression of existing non index lesions, bone marrow that was negative and is now positive, new circulating lymphoma cells in blood cell count and/or pleural fluid, new circulating blasts in the blood cell count), or appearance of new lesions.</description>
          <population>All participants who received at least 1 dose of study treatment (PF-05082566 and/or rituximab) in Portion B, had tumor assessments for lymphoma, and achieved an objective response.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="1"/>
                <count group_id="O10" value="1"/>
                <count group_id="O11" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">The median estimates of time to event, upper and lower limits of 95% CI were not estimable due to the small number of events.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">The median estimates of time to event, upper and lower limits of 95% CI were not estimable due to the small number of events.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="8.0" upper_limit="NA">The median estimates of time to event and upper limit of 95% CI were not estimable due to the small number of events.</measurement>
                    <measurement group_id="O8" value="12.0" lower_limit="2.1" upper_limit="NA">Not estimable due to the small number of events.</measurement>
                    <measurement group_id="O9" value="9.5" lower_limit="NA" upper_limit="NA">Not estimable due to the small number of events.</measurement>
                    <measurement group_id="O10" value="NA" lower_limit="NA" upper_limit="NA">The median estimates of time to event, upper and lower limits of 95% CI were not estimable due to the small number of events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Response in Portion B</title>
        <description>Time to response in Portion B was defined, for participants with an objective response (BOR of CR or PR per Cheson 2007 criteria), as the time from Cycle 1 Day 1 to the first documentation of objective response. BOR of CR or PR per Cheson 2007: CR or PR of index lesions (complete disappearance of all detectable clinical and radiographic evidence of disease, all lymph nodes returned to normal size, spleen and/or liver if enlarged prior to therapy became normal or no longer palpable; or &gt;=50% decrease in the SPD of up to 6 index lesions, no increase in size of other nodes, liver or spleen), without PD of non-index lesions (ie, without: new nonnodal lesion, new nodal lesion &gt;=15 mm in GTD, unequivocal progression of existing non index lesions, bone marrow that was negative and is now positive, new circulating lymphoma cells in blood cell count and/or pleural fluid, new circulating blasts in the blood cell count), and without any new lesions.</description>
        <time_frame>Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)</time_frame>
        <population>All participants who received at least 1 dose of study treatment (PF-05082566 and/or rituximab) in Portion B, had tumor assessments for lymphoma, and achieved an objective response.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion B: PF-05082566 0.03mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks in combination with rituximab (375 milligrams per square meter [mg/m^2] intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion B: PF-05082566 0.06mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion B: PF-05082566 0.12mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion B: PF-05082566 0.18mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion B: PF-05082566 0.24mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion B: PF-05082566 0.3mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion B: PF-05082566 0.6mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion B: PF-05082566 1.2mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion B: PF-05082566 2.4mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion B: PF-05082566 5mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion B: PF-05082566 10mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Response in Portion B</title>
          <description>Time to response in Portion B was defined, for participants with an objective response (BOR of CR or PR per Cheson 2007 criteria), as the time from Cycle 1 Day 1 to the first documentation of objective response. BOR of CR or PR per Cheson 2007: CR or PR of index lesions (complete disappearance of all detectable clinical and radiographic evidence of disease, all lymph nodes returned to normal size, spleen and/or liver if enlarged prior to therapy became normal or no longer palpable; or &gt;=50% decrease in the SPD of up to 6 index lesions, no increase in size of other nodes, liver or spleen), without PD of non-index lesions (ie, without: new nonnodal lesion, new nodal lesion &gt;=15 mm in GTD, unequivocal progression of existing non index lesions, bone marrow that was negative and is now positive, new circulating lymphoma cells in blood cell count and/or pleural fluid, new circulating blasts in the blood cell count), and without any new lesions.</description>
          <population>All participants who received at least 1 dose of study treatment (PF-05082566 and/or rituximab) in Portion B, had tumor assessments for lymphoma, and achieved an objective response.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="1"/>
                <count group_id="O10" value="1"/>
                <count group_id="O11" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="2.1" upper_limit="2.1"/>
                    <measurement group_id="O3" value="2.1" lower_limit="2.1" upper_limit="2.1"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.9" upper_limit="2.1"/>
                    <measurement group_id="O8" value="2.1" lower_limit="1.9" upper_limit="2.2"/>
                    <measurement group_id="O9" value="3.9" lower_limit="3.9" upper_limit="3.9"/>
                    <measurement group_id="O10" value="7.4" lower_limit="7.4" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-Free Survival in Portion B</title>
        <description>Progression-free survival in Portion B was defined as the time from Cycle 1 Day 1 to the date of the first documentation of objective PD (per Cheson 2007) or death due to any cause, whichever occurred first. Objective PD per Cheson 2007 was defined as: PD of index lesions (&gt;=50% increase in SPD of previously involved sites from nadir), or PD of non-index lesions (new nonnodal lesion, new nodal lesion &gt;=15 mm in GTD, unequivocal progression of existing non index lesions, bone marrow that was negative and is now positive, new circulating lymphoma cells in blood cell count and/or pleural fluid, new circulating blasts in the blood cell count), or appearance of new lesions.</description>
        <time_frame>Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)</time_frame>
        <population>All participants who received at least 1 dose of study treatment (PF-05082566 and/or rituximab) in Portion B and had tumor assessments for lymphoma.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion B: PF-05082566 0.03mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks in combination with rituximab (375 milligrams per square meter [mg/m^2] intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion B: PF-05082566 0.06mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion B: PF-05082566 0.12mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion B: PF-05082566 0.18mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion B: PF-05082566 0.24mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion B: PF-05082566 0.3mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion B: PF-05082566 0.6mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion B: PF-05082566 1.2mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion B: PF-05082566 2.4mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion B: PF-05082566 5mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion B: PF-05082566 10mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival in Portion B</title>
          <description>Progression-free survival in Portion B was defined as the time from Cycle 1 Day 1 to the date of the first documentation of objective PD (per Cheson 2007) or death due to any cause, whichever occurred first. Objective PD per Cheson 2007 was defined as: PD of index lesions (&gt;=50% increase in SPD of previously involved sites from nadir), or PD of non-index lesions (new nonnodal lesion, new nodal lesion &gt;=15 mm in GTD, unequivocal progression of existing non index lesions, bone marrow that was negative and is now positive, new circulating lymphoma cells in blood cell count and/or pleural fluid, new circulating blasts in the blood cell count), or appearance of new lesions.</description>
          <population>All participants who received at least 1 dose of study treatment (PF-05082566 and/or rituximab) in Portion B and had tumor assessments for lymphoma.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="31"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="7.4" upper_limit="NA">The median estimates of time to event and upper limit of 95% CI were not estimable due to the small number of events.</measurement>
                    <measurement group_id="O2" value="8.1" lower_limit="1.9" upper_limit="8.1"/>
                    <measurement group_id="O3" value="11.8" lower_limit="3.9" upper_limit="NA">The upper limit of 95% CI was not estimable due to the small number of events.</measurement>
                    <measurement group_id="O4" value="9.9" lower_limit="6.0" upper_limit="NA">The upper limit of 95% CI was not estimable due to the small number of events.</measurement>
                    <measurement group_id="O5" value="2.1" lower_limit="1.8" upper_limit="2.1"/>
                    <measurement group_id="O6" value="5.7" lower_limit="3.9" upper_limit="NA">The upper limit of 95% CI was not estimable due to the small number of events.</measurement>
                    <measurement group_id="O7" value="4.8" lower_limit="0.7" upper_limit="9.4"/>
                    <measurement group_id="O8" value="3.9" lower_limit="2.1" upper_limit="5.7"/>
                    <measurement group_id="O9" value="16.3" lower_limit="13.4" upper_limit="19.2"/>
                    <measurement group_id="O10" value="3.9" lower_limit="2.1" upper_limit="NA">The upper limit of 95% CI was not estimable due to the small number of events.</measurement>
                    <measurement group_id="O11" value="3.0" lower_limit="2.1" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival in Portion B</title>
        <description>Overall survival was defined as the time from Cycle 1 Day 1 to the date of death due to any cause.</description>
        <time_frame>Every 8 weeks from Cycle 1 Day 1 for the first 10 months on study treatment, then every 16 weeks till follow-up visit (assessed up to approximately 2 years)</time_frame>
        <population>All participants who received at least 1 dose of study treatment (PF-05082566 and/or rituximab) in Portion B and had tumor assessments for lymphoma.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion B: PF-05082566 0.03mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks in combination with rituximab (375 milligrams per square meter [mg/m^2] intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion B: PF-05082566 0.06mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion B: PF-05082566 0.12mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion B: PF-05082566 0.18mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion B: PF-05082566 0.24mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion B: PF-05082566 0.3mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion B: PF-05082566 0.6mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion B: PF-05082566 1.2mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion B: PF-05082566 2.4mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion B: PF-05082566 5mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion B: PF-05082566 10mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival in Portion B</title>
          <description>Overall survival was defined as the time from Cycle 1 Day 1 to the date of death due to any cause.</description>
          <population>All participants who received at least 1 dose of study treatment (PF-05082566 and/or rituximab) in Portion B and had tumor assessments for lymphoma.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="31"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Not estimable due to the small number of events.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Not estimable due to the small number of events.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Not estimable due to the small number of events.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Not estimable due to the small number of events.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="9.6" upper_limit="NA">Not estimable due to the small number of events.</measurement>
                    <measurement group_id="O6" value="50.2" lower_limit="NA" upper_limit="NA">Not estimable due to the small number of events.</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="0.7" upper_limit="NA">Not estimable due to the small number of events.</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="18.0" upper_limit="NA">Not estimable due to the small number of events.</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="39.5" upper_limit="NA">Not estimable due to the small number of events.</measurement>
                    <measurement group_id="O10" value="NA" lower_limit="5.4" upper_limit="NA">Not estimable due to the small number of events.</measurement>
                    <measurement group_id="O11" value="NA" lower_limit="4.9" upper_limit="NA">Not estimable due to the small number of events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Biomarkers Linked With Immunomodulation and Cytokine Release</title>
        <description>This was an exploratory endpoint and no data were collected.</description>
        <time_frame>Days 1, 14, 29 and 57</time_frame>
        <population>This was an exploratory endpoint and no data were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion A: PF-05082566 0.006mg/kg</title>
            <description>Participants received PF-05082566 0.006 milligrams per kilogram (mg/kg) intravenously once every 4 weeks (q4wks) as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion A: PF-05082566 0.03mg/kg</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion A: PF-05082566 0.06mg/kg</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion A: PF-05082566 0.12mg/kg</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion A: PF-05082566 0.18mg/kg</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion A: PF-05082566 0.24mg/kg</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion A: PF-05082566 0.3mg/kg</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion A: PF-05082566 0.6mg/kg</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion A: PF-05082566 1.2mg/kg</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion A: PF-05082566 2.4mg/kg</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion A: PF-05082566 5mg/kg</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O12">
            <title>Portion A: PF-05082566 10mg/kg</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O13">
            <title>Portion B: PF-05082566 0.03mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks in combination with rituximab (375 milligrams per square meter [mg/m^2] intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O14">
            <title>Portion B: PF-05082566 0.06mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O15">
            <title>Portion B: PF-05082566 0.12mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O16">
            <title>Portion B: PF-05082566 0.18mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O17">
            <title>Portion B: PF-05082566 0.24mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O18">
            <title>Portion B: PF-05082566 0.3mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O19">
            <title>Portion B: PF-05082566 0.6mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O20">
            <title>Portion B: PF-05082566 1.2mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O21">
            <title>Portion B: PF-05082566 2.4mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O22">
            <title>Portion B: PF-05082566 5mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O23">
            <title>Portion B: PF-05082566 10mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarkers Linked With Immunomodulation and Cytokine Release</title>
          <description>This was an exploratory endpoint and no data were collected.</description>
          <population>This was an exploratory endpoint and no data were collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="0"/>
                <count group_id="O15" value="0"/>
                <count group_id="O16" value="0"/>
                <count group_id="O17" value="0"/>
                <count group_id="O18" value="0"/>
                <count group_id="O19" value="0"/>
                <count group_id="O20" value="0"/>
                <count group_id="O21" value="0"/>
                <count group_id="O22" value="0"/>
                <count group_id="O23" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Exploratory Pharmacodynamic Biomarkers</title>
        <description>This was an exploratory endpoint and no data were collected.</description>
        <time_frame>Days 1 and 21</time_frame>
        <population>This was an exploratory endpoint and no data were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion A: PF-05082566 0.006mg/kg</title>
            <description>Participants received PF-05082566 0.006 milligrams per kilogram (mg/kg) intravenously once every 4 weeks (q4wks) as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion A: PF-05082566 0.03mg/kg</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion A: PF-05082566 0.06mg/kg</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion A: PF-05082566 0.12mg/kg</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion A: PF-05082566 0.18mg/kg</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion A: PF-05082566 0.24mg/kg</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion A: PF-05082566 0.3mg/kg</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion A: PF-05082566 0.6mg/kg</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion A: PF-05082566 1.2mg/kg</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion A: PF-05082566 2.4mg/kg</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion A: PF-05082566 5mg/kg</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O12">
            <title>Portion A: PF-05082566 10mg/kg</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O13">
            <title>Portion B: PF-05082566 0.03mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks in combination with rituximab (375 milligrams per square meter [mg/m^2] intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O14">
            <title>Portion B: PF-05082566 0.06mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O15">
            <title>Portion B: PF-05082566 0.12mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O16">
            <title>Portion B: PF-05082566 0.18mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O17">
            <title>Portion B: PF-05082566 0.24mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O18">
            <title>Portion B: PF-05082566 0.3mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O19">
            <title>Portion B: PF-05082566 0.6mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O20">
            <title>Portion B: PF-05082566 1.2mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O21">
            <title>Portion B: PF-05082566 2.4mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O22">
            <title>Portion B: PF-05082566 5mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O23">
            <title>Portion B: PF-05082566 10mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory Pharmacodynamic Biomarkers</title>
          <description>This was an exploratory endpoint and no data were collected.</description>
          <population>This was an exploratory endpoint and no data were collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="0"/>
                <count group_id="O15" value="0"/>
                <count group_id="O16" value="0"/>
                <count group_id="O17" value="0"/>
                <count group_id="O18" value="0"/>
                <count group_id="O19" value="0"/>
                <count group_id="O20" value="0"/>
                <count group_id="O21" value="0"/>
                <count group_id="O22" value="0"/>
                <count group_id="O23" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient-Reported Outcomes of PF-05082566 and Rituximab When Given in Combination in Follicular Lymphoma Participants</title>
        <description>This was an exploratory endpoint and was not evaluated. Patient-reported outcome questionnaires were not completed as a result of administrative processing error.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>This was an exploratory endpoint and was not evaluated. Patient-reported outcome questionnaires were not completed as a result of administrative processing error.</population>
        <group_list>
          <group group_id="O1">
            <title>Portion A: PF-05082566 0.006mg/kg</title>
            <description>Participants received PF-05082566 0.006 milligrams per kilogram (mg/kg) intravenously once every 4 weeks (q4wks) as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O2">
            <title>Portion A: PF-05082566 0.03mg/kg</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O3">
            <title>Portion A: PF-05082566 0.06mg/kg</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O4">
            <title>Portion A: PF-05082566 0.12mg/kg</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O5">
            <title>Portion A: PF-05082566 0.18mg/kg</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O6">
            <title>Portion A: PF-05082566 0.24mg/kg</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O7">
            <title>Portion A: PF-05082566 0.3mg/kg</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O8">
            <title>Portion A: PF-05082566 0.6mg/kg</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O9">
            <title>Portion A: PF-05082566 1.2mg/kg</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O10">
            <title>Portion A: PF-05082566 2.4mg/kg</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O11">
            <title>Portion A: PF-05082566 5mg/kg</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O12">
            <title>Portion A: PF-05082566 10mg/kg</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O13">
            <title>Portion B: PF-05082566 0.03mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks in combination with rituximab (375 milligrams per square meter [mg/m^2] intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O14">
            <title>Portion B: PF-05082566 0.06mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O15">
            <title>Portion B: PF-05082566 0.12mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O16">
            <title>Portion B: PF-05082566 0.18mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O17">
            <title>Portion B: PF-05082566 0.24mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O18">
            <title>Portion B: PF-05082566 0.3mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O19">
            <title>Portion B: PF-05082566 0.6mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O20">
            <title>Portion B: PF-05082566 1.2mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O21">
            <title>Portion B: PF-05082566 2.4mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O22">
            <title>Portion B: PF-05082566 5mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 5mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
          <group group_id="O23">
            <title>Portion B: PF-05082566 10mg/kg + Rituximab 375mg/m^2</title>
            <description>Participants received PF-05082566 10mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient-Reported Outcomes of PF-05082566 and Rituximab When Given in Combination in Follicular Lymphoma Participants</title>
          <description>This was an exploratory endpoint and was not evaluated. Patient-reported outcome questionnaires were not completed as a result of administrative processing error.</description>
          <population>This was an exploratory endpoint and was not evaluated. Patient-reported outcome questionnaires were not completed as a result of administrative processing error.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="0"/>
                <count group_id="O14" value="0"/>
                <count group_id="O15" value="0"/>
                <count group_id="O16" value="0"/>
                <count group_id="O17" value="0"/>
                <count group_id="O18" value="0"/>
                <count group_id="O19" value="0"/>
                <count group_id="O20" value="0"/>
                <count group_id="O21" value="0"/>
                <count group_id="O22" value="0"/>
                <count group_id="O23" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to approximately 4 years.</time_frame>
      <desc>The same event may appear as both an AE and an SAE. However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as non-serious in another participant, or 1 participant may have experienced both a serious and non-serious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Portion A: PF-05082566 0.006mg/kg</title>
          <description>Participants received PF-05082566 0.006 milligrams per kilogram (mg/kg) intravenously once every 4 weeks (q4wks) as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="E2">
          <title>Portion A: PF-05082566 0.03mg/kg</title>
          <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="E3">
          <title>Portion A: PF-05082566 0.06mg/kg</title>
          <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="E4">
          <title>Portion A: PF-05082566 0.12mg/kg</title>
          <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="E5">
          <title>Portion A: PF-05082566 0.18mg/kg</title>
          <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="E6">
          <title>Portion A: PF-05082566 0.24mg/kg</title>
          <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="E7">
          <title>Portion A: PF-05082566 0.3mg/kg</title>
          <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="E8">
          <title>Portion A: PF-05082566 0.6mg/kg</title>
          <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="E9">
          <title>Portion A: PF-05082566 1.2mg/kg</title>
          <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="E10">
          <title>Portion A: PF-05082566 2.4mg/kg</title>
          <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="E11">
          <title>Portion A: PF-05082566 5mg/kg</title>
          <description>Participants received PF-05082566 5mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="E12">
          <title>Portion A: PF-05082566 10mg/kg</title>
          <description>Participants received PF-05082566 10mg/kg intravenously q4wks as a single agent in Portion A, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="E13">
          <title>Portion B: PF-05082566 0.03mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 0.03mg/kg intravenously q4wks in combination with rituximab (375 milligrams per square meter [mg/m^2] intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="E14">
          <title>Portion B: PF-05082566 0.06mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 0.06mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="E15">
          <title>Portion B: PF-05082566 0.12mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 0.12mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="E16">
          <title>Portion B: PF-05082566 0.18mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 0.18mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="E17">
          <title>Portion B: PF-05082566 0.24mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 0.24mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="E18">
          <title>Portion B: PF-05082566 0.3mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 0.3mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="E19">
          <title>Portion B: PF-05082566 0.6mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 0.6mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="E20">
          <title>Portion B: PF-05082566 1.2mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 1.2mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="E21">
          <title>Portion B: PF-05082566 2.4mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 2.4mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="E22">
          <title>Portion B: PF-05082566 5mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 5mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
        <group group_id="E23">
          <title>Portion B: PF-05082566 10mg/kg + Rituximab 375mg/m^2</title>
          <description>Participants received PF-05082566 10mg/kg intravenously q4wks in combination with rituximab (375mg/m^2 intravenously, every week during the first 4 weeks) in Portion B, for up to 2 years or until participant permanently discontinued study treatment, whichever occurred earlier.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="27" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="21" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="9" subjects_at_risk="11"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E20" subjects_affected="8" subjects_at_risk="32"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E22" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E23" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E20" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Large intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Oesophageal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus chorioretinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Stress fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Intracranial tumour haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Idiopathic pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="36" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="23" subjects_at_risk="31"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="9" subjects_at_risk="11"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E19" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E20" subjects_affected="29" subjects_at_risk="32"/>
                <counts group_id="E21" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E22" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E23" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="6" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="5" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E21" events="4" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E22" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E20" events="2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Orbital oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="7" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="3" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="8" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E20" events="8" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="3" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="10" subjects_affected="9" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="11" subjects_affected="10" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="5" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="4" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E22" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="5" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Oral disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E22" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Device related thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="19" subjects_affected="18" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E9" events="10" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E19" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E20" events="7" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="3" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E23" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Implant site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="11" subjects_affected="9" subjects_at_risk="42"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E20" events="6" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Early satiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infusion site oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Ill-defined disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Mucosal dryness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="4" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Tinea versicolour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E15" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E20" events="10" subjects_affected="8" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Scratch</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E21" events="3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E21" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="5" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="8" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E20" events="5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="7" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="3" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="3" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="5" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="8" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Muscle fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E20" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E20" events="5" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E23" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Urinary hesitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Urine abnormality</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Oedema genital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E20" events="7" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Increased upper airway secretion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E22" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Oropharyngeal plaque</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="4" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="3" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="3" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E21" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E20" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Seborrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Skin plaque</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E20" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E19" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E20" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E21" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E22" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E23" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

